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1 Introduction  
 
Hepatitis C, which was identified in 1989 as non-A, non-B hepatitis, represents an immense 
global health problem. According to the World Health Organization (WHO) 130-170 million 
people are infected worldwide which is around 3% of the world’s population. Over 350 000 
infected people die from hepatitis C virus (HCV)-related diseases every year.  
The liver is the major site of HCV infection. Hepatitis C causes acute and chronic liver 
disease which can lead to cirrhosis, liver failure and hepatocellular carcinoma. Furthermore, 
different studies detected HCV RNA in cells other than hepatocytes (Lemon et al. 2007). 
Evidence for extrahepatic replication was found in the central nervous system, lymphoid cells 
and gut epithelial cells (Lindenbach et al. 2007). Though, the relevance of these findings 
remains uncertain and controversial.   
Current HCV therapies have to be improved as standard therapy with a combination of 
ribavarin and pegylated interferon-α is ineffective. It permanently eliminates detectable virus 
in only around 40% of genotype 1 infected patients and around 70-80% of patients infected 
with genotype 2 (Manns et al. 2001). The therapy is often poorly tolerated and provides many 
side effects. No primary preventions, no vaccines and no post-exposure prophylaxis were 
developed so far (Lemon et al. 2007). Studying the hepatitis C virus life cycle can reveal new 
approaches for the development of vaccines or new antiviral therapies. Different steps in the 
HCV life cycle are possible targets for new therapeutic drugs.  
1.1 Classification 
 
The hepatitis C virus is an enveloped single-stranded RNA virus with positive polarity 
(ss(+)RNA). It is a member of the Flaviviridae family and classified in the Hepacivirus genus 
(Choo et al. 1991).  
HCV shows extraordinary genetic variability due to its abundant virus production rate, high 
error rate and lack of proofreading activity of the RNA-dependent RNA polymerase (RdRp)  
(Pawlotsky 2003). Based on the genetic differences six major genotypes could be 
determined. These variants differ up to 30% in their sequence over the entire genome. The 
six genotypes can be further divided into several subtypes. Minor sequence variations, 
around 1-2%, are common. These so called ‘quasispecies’ co-circulate within single infected 
individuals. Genetic relationship between genotypes and regions of distribution are shown in 
Figure 1 (Simmonds 2004). 





Figure 1 Phylogenetic tree of major HCV genotypes and subtypes (Simmonds 2004 p. 3176). Evolutionary distances and 
regions of distribution are shown.  
 
1.2 Virion structure 
 
HCV particles are described by filtration and electron microscope (EM) techniques to be 
between 30 and 80 nm in diameter (He et al. 1987; Yuasa et al. 1991). EM images show 
spherical virions containing an electron dense core surrounded by a lipid envelope (Wakita et 
al. 2005). HCV RNA is thought to be encapsidated by core proteins surrounded by a lipid 
layer including HCV glycoproteins E1 and E2. A model of the HCV virion is shown in figure 
2A. Furthermore, HCV shows an unusually low buoyant density between 1.03 to 1.10 g/ml 
(Bradley et al. 1991; Hijikata et al. 1993). This is likely explained by its described interactions 
with lipoproteins (Lindenbach et al. 2007). 





Figure 2 HCV virion structure. (A) Model of a HCV virion. A lipid envelope containing HCV glycoproteins E1 and E2 
surrounds the core-encapsidated viral genome. (B) EM image of a HCV virion (Wakita et al. 2005 p.793). Particle was 
detected by immunogold labeling for E2.  
 
1.3 HCV genome 
 
The HCV genome is uncapped and about 9.6kb in size (Lindenbach et al. 2007). 
The genome is coding for one large polyprotein (about 3011 amino acids in size) that is 
proteolytically cleaved into ten viral proteins. The polyprotein is flanked by N and C terminal 
non-coding regions (NTRs or NCRs). The 5’ NTR includes an internal ribosome entry site 
(IRES) which mediates polyprotein translation (Wang et al. 1993). Furthermore both NTRs 
are required for viral replication (Wang et al. 1993; Friebe et al. 2001). 
Proteins can be divided into structural and non-structural proteins. Amino terminal one third 
of the polyprotein includes the viral structural proteins core protein (C) and envelope 
glycoproteins E1 and E2. Between structural and non-structural HCV proteins a small 
integral membrane protein (p7) is found. The actual function of p7 as a structural or non-
structural protein is unknown. The remainder of the polyprotein contains the non-structural 
proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B which coordinate the viral life cycle 
(Bartenschlager et al. 2004). 
Next to these proteins at least three different forms of alternative reading frame proteins 
(ARF) or frameshift (F) proteins are described. Translation of this protein is also initiated at 
the core gene start codon and alternative proteins are produced through frameshifting. These 








HCV protein Size [kDa] Main function Source 
Core 21 (mature 
form) 
Nucleocapsid protein, RNA binding Lindenbach et al. 
2007 
E1 30 Envelope protein Lindenbach et al. 
2007 
E2 70 Envelope protein Lindenbach et al. 
2007 
p7    7 Unknown, probably ion channel Lindenbach et al. 
2007 
NS2 23 NS2-NS3 proteinase, assembly Lindenbach et al. 
2007 
NS3 70 NS2-NS3 proteinase, NS3-NS4A 
proteinase, helicase, NTPase, RNA 
binding, assembly? 
Lindenbach et al. 
2007 
NS4A 8 Co-factor NS3-NS4a proteinase Lindenbach et al. 
2007 
NS4B 27 Integral membrane protein, organizing 
membrane-bound replication complex, 
phosphorylation NS5A 
Lindenbach et al. 
2007 
NS5A 58 Replication Lindenbach et al. 
2007 
NS5B 68 Major enzyme of RNA replication (RNA 
dependent RNA polymerase) 
Lindenbach et al. 
2007 
ARF proteins Unknown Unknown  Xu, 2001 
Table 1 Structural and non-structural HCV proteins. 
 
The polyprotein is co-and posttranslational cleaved by viral and host cell proteases. The 
region between core and NS2 is processed by the host cell signal peptidase. Maturation of 
core protein requires releasing its association to the E1 signal peptide. This is performed by 
the signal peptide peptidase. NS2 and NS3 are separated by NS2-NS3 cysteine 
autoprotease cleavage. The remainder of the polyprotein is processed by NS3-NS4A serine 
protease cleavage (Bartenschlager et al. 2004). 





Figure 3 HCV genome structure and polyprotein processing. (A) Genome structure of HCV. The open reading frame (ORF) 
is flanked by non-coding regions (NTR). The genome is lacking a cap-structure. Internal ribosome entry site (IRES) is located 
within the 5’ non-coding region. Four major domains (I-IV) of the 5’ NTR are labeled. The 3’ non-coding region includes a 
variable region (V), a poly U part and a conserved region (X-tail). (B) Translation produces a polyprotein of about 3011 
amino acid in size. Polyprotein is co-and post-translational processed into 10 proteins (Frameshift leads to an alternative 
11th protein). Structural proteins are highlighted in blue. Cleavage sites are indicated by arrowheads and circles. Signal 
peptidase (SP) cleavage sites are marked by open arrowheads, signal peptide peptidase (SPP) cleavage by a filled 
arrowhead, NS2-NS3 cysteine autoprotease cleavage by an open circle and NS3-NS4 serine protease cleavage by filled 
circles. (C) Membrane topology of HCV proteins. Core is show pre-SPP-cleavage and still in its membrane anchored form. E1 
and E2 are shown post-SP-cleavage and after reorientation of the C-termini. Further details are found in the text 
(Lindenbach et al. 2007). 
 
1.3.1 Non-coding regions 
1.3.1.1 5’-Non-coding region (5’NTR) 
 
The 5’NTR is a well conserved, 341 nucleotide long RNA sequence. Among HCV genotypes 
sequence identicalness of the 5’ non-translating region is more than 90% (Shi and Lai 2006). 




The secondary and tertiary structure is quite complex and consists of four domains (I-IV) and 
a pseudoknot (ψ) (Wang et al. 1993). It does not contain a 5’ methyl cap structure. Domain I, 
the first 40 nucleotides of 5’NTR, is important for replication, similar to other positive ssRNA 
viruses. The remainder of the 5’NTR is essential for translation. It includes the internal 
ribosome entry site (IRES). IRES also overlaps first nucleotides of the HCV coding region 
though it is not clear whether it is a functional component of IRES or only interacts with it by 
stabilizing the complex secondary structure (Krekulová et al. 2006; Reynolds et al. 1995). 
IRES coordinates the cap-independent translation of the HCV genome (Shi and Lai 2006).  
1.3.1.2 3’-Non-coding region (3’NTR) 
 
3’NTR follows the UGA termination codon of the coding region. Length of 3’NTR varies 
between 200 and 235 nt. It consists of a short variable region of about 40 nt, a 
polyuridine/polypyrimidine (poly(U/UC) tract of a heterogeneous length and a highly 
conserved 3’X domain of 98 nt (X-tail) (Krekulová et al. 2006). Mutagenesis studies of Friebe 
et al. (2001) mapped regions of the 3’NTR which are important for replication. These studies 
revealed that the X-tail is especially important for replication. The poly(U/UC) tract needs to 
be at least 26 nt long to allow replication. Deletion of the variable region also reduces 
replication significantly. Studies of You and Rice (2008) revealed that RNA replication 
requires a functional long distance kissing-loop structure between stem-loop 2 (SL2) of the 3’ 
X-tail and an element of NS5B within the coding region. This could explain why a short 
poly(U/UC)-tract disables replication as the poly(U/UC) could function as a spacer for these 
long distance base-pairing interactions. However, the actual function of the kissing 
interaction remains to be determined (You and Rice 2008). 
1.3.2 Structural Proteins 
1.3.2.1 Core Protein 
 
Core protein is a highly conserved protein which plays an important role in virus particle 
assembly. It is characterized to form the main component of the HCV nucleocapsid. As 
mentioned above core protein is processed in two steps. Host signal peptidase removes an 
immature membrane anchored form of core (191 aa) from the polyprotein. Further cleavage 
of the signal peptide peptidase within the membrane anchor between amino acid 173 and 
182 releases the 21 kDa mature core protein (Krekulová et al. 2006; Dubuisson 2007; 
Lindenbach et al. 2007). 
After processing the mature form of the core protein can be separated into two domains: an 
122 aa N-terminal hydrophilic domain and a C-terminal hydrophobic domain of around 50 aa 
(Krekulová et al. 2006). Domain I can bind RNA unspecifically. It is shown that interaction of 




the N-terminal part of domain I with the 5’NCR can influence IRES function resulting in down-
regulation of translation (Honda et al. 1996). Domain II is involved in proper folding of domain 
I and mediates the binding of core to lipid droplets and membranes (Lindenbach et al. 2007). 
E1 has been shown to interact with core which seems to be necessary for particle assembly 
(Lo et al. 1995). Core protein also assist in proper folding of E1 (Merola et al. 2001). 
The mature form of the protein multimerizes and binds the HCV genome forming the viral 
nucleocapsid in virus particle assembly.  
Next to this structural function core is found to additionally influence different cellular 
pathways of the host cell like transcription, apoptosis, lipid metabolism and immune response 
(McLauchlan 2000). A likely explanation of these functions is the interaction of core with host 
cell proteins. Furthermore, core can bind lipid droplets inducing steatosis in transgenic mice 
with over-expressed core protein. Interaction with TNF, Fas, NF-κB most probably influences 
immune response and apoptosis. These reactions might be important in the development of 
chronic infections (Krekulová et al. 2006). 
Furthermore core protein is described to control gene expression by binding human DEAD 
box protein 3 (DDX3) from the DEAD-box RNA helicase family. This might influence 
transcription, pre-mRNA splicing and other reactions of RNA metabolism of the host cell 
(Owsianka and Patel 1999). 
1.3.2.2 Envelope Glycoproteins (E1 and E2) 
 
HCV envelope glycoproteins E1 and E2 are type-I transmembrane proteins. The about 30 
kDa (E1) and 70 kDa (E2) proteins contain a large N-terminal extracellular domain and a C-
terminal transmembrane domain. E1 and E2 are essential for virus entry. They are likely to 
mediate virus particle attachment and membrane fusion. They also participate in virion 
assembly (Dubuisson 2007). Extracellular functional units of E1 and E2 are suggested as 
non-covalent E1-E2 heterodimers, which are highly glycosylated (Bartosch and Cosset 
2006). The E1-E2 heterodimers are suggested to function as a ligand for cellular receptors. 
Several potential receptors could be identified, from which CD81 tetraspanin and scavenger 
receptor class B type I (SR-BI) could be determined to play a role in HCV entry (Cocquerel et 
al. 2006). Transmembrane domains are thought to function as membrane anchors and also 
as signal peptides influencing localization and heterodimerization of the extracellular 
domains (Bartosch, Cosset 2006). 
 
 




1.3.3 Non-structural proteins 
1.3.3.1 p7 
 
p7 is a small integral membrane protein. It is believed that it spans the membrane twice with 
both N- and C-termini facing the ER lumen (Carrere-Kremer et al. 2002). It is suggested to 
function as an ion-channel, but the role of p7 in the viral life cycle remains unclear. It is also 
unclear if it is a structural or a non-structural protein. It is predicted that p7 is not a 
component of the virion (Jones CT et al. 2007). Protein p7 could be localized in the ER, 
mitochondria and the plasma membrane of hepatocytes (Carrere-Kremer et al. 2002). It is 
referred to be able to multimerize in vitro forming membrane calcium ion channels which can 
be blocked by amantadine (Griffin et al. 2003). Sakai et al. (2003) showed that p7 is essential 
for infectivity in vivo. Work with subgenomic replicons which do not include p7 revealed that it 
is not necessary for HCV RNA replication (Lohmann et al. 1999). The role of p7 remains 
unclear to date, but one can assume that it might play a role in viral entry and release alike 
similar viral transmembrane channels in other viruses (Lindenbach et al. 2007).  
1.3.3.2 NS2 
 
NS2 is an integral polytopic membrane protein. The actual topology of NS2 is not clear yet, 
but it is suggested that it spans the membrane four times with N-and C-termini facing the ER 
lumen (Yamaga and Ou 2002). The N-terminus of NS2 is cleaved from p7 by a signal 
peptide peptidase within the ER. The C-terminal domain functions as cysteine protease 
which requires the N-terminal protease domain of NS3 (first 180 residues). It is suggested 
that NS3 is needed to stabilize protein folding (Welbourn and Pause 2007). The NS2/3-
autoprotease cleaves the NS2/NS3 junction in an independent manner from NS3/NS4 
protease activity (Lindenbach et al. 2007).  
For correct function of the protease the coordination of a zinc molecule by NS3 residues 
1123, 1127, 1171 and 1175 are needed to stabilize NS2/3 structure (Welbourn and Pause 
2007). As the NS2/3 protease cleavage takes place in the cytosolic space, it is suggested 
that the NS2/NS3 region has to be re-orientated after NS2/3 cleavage (Dubuisson 2007). 
Furthermore, recent data also reveals that NS2 plays a role in virus particle assembly. It is 
also suggested that it is involved in particle release. But its precise role in these processes is 
unknown to date. The Lindenbach laboratory as well as other groups recently published 
protein-protein interactions between NS2 and other HCV proteins which might be essential 
for virus particle assembly (Stapleford and Lindenbach 2011; Ma et al. 2011). It is suggested 
that NS2 organizes particle assembly by these protein-protein interactions recruiting HCV 
protein complexes to sites of assembly reactions close to lipid droplets (Jirasko et al. 2010).  






The HCV NS3 is a multifunctional protein which is around 70 kDa in size. The N-terminal one 
third contains a serine protease and the C-terminal two thirds contain a RNA helicase. The 
protease processes the HCV polyproteins non-structural region and also some cellular 
proteins. The exact function of the helicase remains unclear so far. 
1.3.3.3.1   NS3 Protease (NS3prot) 
 
The serine protease domain of NS3 belongs to the superfamily of trypsin/chemotrypsin 
proteases. NS3 protease is responsible for cleavage of the HCV polyprotein at the NS3/4A, 
NS4A/4B, NS4B/5A and NS5A/5B sites (Figure 3). In addition to its role in polyprotein 
processing NS3 protease is also involved in proteolytic cleavage of host cell proteins which 
are involved in intracellular viral responses. This causes decreased expression of multiple 
host defense genes contributing to the development of persistent infections (Li et al. 2005).  
The structure of NS3 protease reveals two β-barrel domains adjoined by two small α-helices. 
Substrate binding is located in a cleft between the β-barrel domains. Interaction with NS4A is 
required for complete folding and activity of the NS3 serine protease. It also contributes in 
positioning of the catalytic triad and the substrate (Barbato et al. 1999). Next to stabilizing the 
proteins conformation NS4A is told to serve as a membrane anchor with its N-terminal 
hydrophobic domain (Wölk et al. 2000). Furthermore a Zn2+ ion is required to stabilize the 
structure. Zn2+ is coordinated by three cysteine residues and one histidine (De Francesco et 
al. 1996). 
The cleavage mechanism of the NS3 protease is identical to the one of other serine 
proteases. A catalytic triad is found in the active site of NS3 protease. It consist of three 
amino acids, Ser-139, His-57 and Aps-81 which are essential for catalysis of peptide 
cleavage. Substrate binding leads to ordered reactions of the peptide cleave mechanism. 
Several intermediates are generated releasing the polypeptide bond of the substrate by 
hydrolysis (Raney et al. 2010). 
1.3.3.3.2   NS3 helicase (NS3hel) 
 
Helicases are proteins that separate double-stranded nucleic acids into single-strands in an 
NTP-dependent reaction. Helicases are involved in several cellular functions such as pre-
mRNA splicing, ribosome assembly, translation initiation and other cellular RNA transactions 
(Tai et al. 1996; Jankowsky and Fairman 2007). Helicases can be divided into five major 
superfamilies (SF 1-5) based on sequence homology (Gorbalenya and Koonin 1993). SF-2 is 
further divided into several subgroups (DEAD, DExH, etc). NS3 helicase (NS3hel) domain is 
a superfamily 2 (SF-2) DExH helicase/NTPase. Other members of SF-2 DExH helicases 




include Yellow fever virus NS3, Dengue fever virus NS3 and Vaccina virus NPH-II 
(Jankowsky 2010). SF-1 and SF-2 proteins are characterized by sequence motifs involved in 
ATP binding and hydrolysis which are well conserved within each subgroup (see figure 5). 
The complete biological role of HCV NS3 helicase is not yet known. It has been shown that it 
is essential for viral RNA replication and infectivity (Lindenbach et al. 2007). Furthermore, its 
role in virus particle assembly is assumed. 
1.3.3.3.3  NS3hel structure 
 
HCV NS3hel has three structural domains, two parallel α-β domains and one α-helices-rich 
domain. These three domains are nearly equal in size and form a triangular shaped 
molecule. Between the two parallel α-β domains (RecA like domains 1 and 2) and domain 3 
is a ssRNA binding groove. ssRNAs are bound through non-hydrophilic interactions between 
some of the residues and phosphate of the nucleic acid backbone. ATP binding is suggested 
between domain 1 and domain 2 (Kim, JL et al. 1998; Yao et al. 1997). 
 
 
Figure 4 NS3hel domains. (A) Location of NS3hel in the genome of HCV. Full length NS3 is located from amino acid 1144 to 
1774 in genotype 2a Jc1 sequence. Numbers highlight protein locations as well as locations of NS3hel domains. Numbering 
is based on full-length replicon Jc1. (B) Model of NS3hel in complex with single-stranded nucleic acid and NTP. Nucleic acids 
are bound in a binding groove between domain 1 and 2 and domain 3. NTPs are bound in a pocket between domain 1 and 2 
(Gu and Rice 2010). NS3hel structure is based on Protein Data Bank Entry 3KQL and was rendered with PyMOL. 




As implied earlier NS3hel contains conserved helicase motifs associated with NTP binding, 
including Walker motif A and B (Motif I and II) (Walker et al. 1982). Walker motif A binds 
terminal phosphate groups of NTP cofactors. Walker motif B which includes signature 
sequence DExH functions as chelator of Mg2+ which is essential for NTP catalysis. 
Conserved helicase motifs line the groove between domain 1 and domain 2 and face the 
ssRNA binding site (Raney et al. 2010). The role of the highly conserved helicase motifs in 
unwinding nucleic acid duplexes was described in structure-function studies by different 
groups (Dillingham et al. 2001; Lin and Kim, JL 1999; Gu, M and Rice 2010).   
 
Figure 5 Conserved helicase motifs of NS3. (A) Ribbon model of NS3. Conserved helicase motifs are colored and marked 
by Roman numbers. Structure is based on Protein Data Bank code 3KQL and rendered with PyMOL. (B) Primary structure of 
NS3hel. Motifs are colored as in A. Domains are highlighted with colored lines. Motifs are marked by Roman numbers. 
Domain 1 is colored yellow, domain 2 blue and domain 3 green matching to transparent surface colors of domains in A.  
 
NS3hel binds RNA as well as DNA. The helicase unwinds duplex DNA and RNA in 3’-5’ 
direction (Gu, M and Rice 2010). Both binding and unwinding of either RNA or DNA are pH 




dependent, they are enhanced at a pH around 6.5. This might suggest that HCV replication 
is located at an unique environment within the membranous web (Lam et al. 2004). Nucleic 
acids are bound more tightly to complete NS3 compared to NS3hel, indicating that the NS3 
protease domain is involved in binding DNA or RNA (Raney et al. 2010).  
 
1.3.3.3.4  Mechanism of unwinding duplex DNA or RNA 
 
NTPases are bound in a pocket between domain 1 and domain 2. ATP is the main 
nucleotide for NTPase activity, but NS3 is non-selective hydrolyzing all ribonucleotides and 
desoxyribonucleotides (Bartenschlager et al. 2004). Motifs I, II, III and V play an important 
role in NTPase activity along with the newly described motif Y (NS3 residue Y241 in domain 
1) (Gu, Rice 2010). Motif Y is not found in other flavivirus helicases, which were supposed to 
be quite similar to HCV NS3hel. This residue is involved in sandwiching the nucleoside base 
with motif V residue T419. NS3hel can bind either dNTPs or NTPs as the helicase does not 
identify the 2’ ribose oxygen (Suzich et al. 1993). Residues of motif I are indicated to stabilize 
the bound NTP for catalysis (Gu, M and Rice 2010).  
 
Figure 6   Important residues for binding NTPs. Figure modified from Raney et al. (2010) p. 22726. ATP transition state 
analog in the bound pocket between domain 1 and 2 is shown. Helicase motifs involved in NTPase activity are highlighted in 
colors.  Motif I is colored red, motif Y is pink, motif III is light blue and motif V in dark green. Residues Y241 and T419 
sandwich NTPs. This bound is stabilized by residues of motif I. 
 
The supposed inchworm model suggests translocation of the helicase by movement of 
domain 1 and 3 in the direction of domain 2 hydrolyzing ATP. Recently Gu and Rice (2010) 
made X-ray crystal structures of NS3 with ssDNA and ATP analogs to find out about the 
molecular mechanisms of unwinding and ATP hydrolysis of NS3hel. The group described 
three conformational stages of NS3hel using ADP∙BeF3 and ADP∙AIF4-. ADP∙BeF3 mimics the 
ground state of ATP and ADP∙AIF4- the ATP hydrolysis state. These studies revealed a close 
view to functional mechanisms of the SF-2 helicase. Residues V432 (domain 2) and W501 
(domain 3) are proposed to form a tight interaction with the nucleic acid. In absence of ATP 
five nucleotides of the nucleic acid are bound to NS3hel blocking unwinding function (Raney 
et al. 2010). Binding NTP leads to conformation change by rotation of domain 1 and 3 in the 




direction of domain 2 (5’ direction) closing the RecA-like domains 1 and 2. This reaction 
results in sliding of the nucleic acid of one nucleotide at the W501 position along the binding 
track in 5’ direction. ATP hydrolysis leads to movement of domain 2 to its initial conformation. 
Within this change back to the initial state 1 base pair of duplex RNA or DNA gets unwinded. 
Residues V432 and W501 were shown to be important for unwinding by anchoring to the 
nucleic acid during conformation changes of the enzyme. Structure-based mutagenesis of 
V432 and W501 showed significant reduction of unwinding activity when mutating these 
residues (Lin and Kim, JL 1999). Essential for unwinding is a β-hairpin (with two conserved 
phenylalanine residues in the turn, also referred as Phe loop) within domain 2 (Saikrishnan et 
al. 2008). The β-hairpin is suggested to serve as a wedge splitting the double-stranded 
nucleic acid. Studies with a SF-1 helicase (RecD2) showed that a removal of the pin stops 
unwinding activity of the helicase demonstrating its important role in separating duplex DNA 
or RNA (Lam et al. 2003).  





Figure 7 Model of NS3hel nucleic acid translocation and unwinding. Ribbon models of NS3 helicase domains are shown. 
Nucleic acids and ATP are simplified for clarity. Domains 1, 2 and 3 are colored yellow, blue and green. The β-hairpin 
structure is highlighted red. (A) Helicase domain with bound nucleic acid in the absence of NTP. Domain 1 and 2 are told to 
form a 27 Å gap (Gu, M and Rice 2010).  (B) With binding ATP NS3hel undergoes a conformational change. Domains 1 and 3 
are rotating in 5’ direction standing closer to domain 2 (~15Å) (Gu, M and Rice 2010).  (C) ATP hydrolysis leads to rotation of 
domain 1 and 3 back to the initial conformation. These conformational changes lead to a movement of one nucleotide per 
hydrolyzed ATP which is indicated by the red arrow. The β-hairpin is described to function as wedge to split duplex DNA or 
RNA (Gu, M and Rice 2010). NS3hel structures are based on Protein data bank entry 3KQK and 3KQL. Models are rendered 
wit PyMOL. The figure was made with the help of the video clip from Gu, M and Rice (2010) (http://www.pnas.org/ 
content/suppl/2009/12/30/0913380107.DCSupplemental/SM1.mov). 






As described above, NS4A is a cofactor of the NS3/4A serine protease. It is important for 
complete folding and positioning of the catalytic triad. Next to stabilizing the proteins 
conformation NS4A is told to serve as a membrane anchor with its N-terminal hydrophobic 
domain. Due to this function it is important for assembly of the replicase complex (Wölk et al. 
2000). Furthermore, it is described to maintain multiple functions in the HCV life cycle. It is 
described to play a role in recognition of RNA by the NS3 protease and helicase. NS4A also 
interacts with NS4B, NS5A and uncleaved NS4B-5A (Lindenbach et al. 2007). The C-




NS4B is a membrane-spanning protein with four central transmembrane domains. N- and C-
termini are facing the cytoplasm (Dubuisson 2007). It is suggested to play an essential role in 
inducing the formation of the membranous web which is important for organizing a 
membrane-bound replication complex (Lindenbach et al. 2007). Furthermore, NS4B reveals 
GTPase activity which is reported to be important for RNA replication (Einav et al. 2004). It is 
also described to inhibit RNA-dependent RNA polymerase activity of NS5B regulating HCV 
replication (Piccininni et al. 2002). 
1.3.3.6 NS5A 
 
NS5A is a phosphoprotein with an essential but unclear role in replication. NS5A contains 
three domains and an N-terminal membrane anchor. Domain I includes a Zn2+ -binding 
domain which is shown to be essential for replication (Tellinghuisen et al. 2005). NS5A is 
found in a phosphorylated (56 kDa) and a hyperphosphorylated (58 kDa) form. The role of 
the different phosphorylation states is not known. Hyperphosphorylation is modulated by 
NS4A. It is shown, that NS5A-hyperphosphorylation leads to enhancement of HCV RNA 
replication. These results indicate, that NS5A-hyperphosphorylation might down-regulate 
RNA replication by disrupting the interaction between NS5A and the human vesicle-
associated membrane protein-associated protein A (hVAP-A) which is involved in 
intracellular vesicle trafficking and might be involved in the HCV replication machinery 
(Evans et al. 2004). NS5A is also suggested to modulate interferon (IFN) response. In this 
manner Domain II might play a role in INF-response by inhibiting protein kinase PKR 
suppressing a host cell IFN-induced antiviral pathway.  
 






NS5B is a RNA-dependent RNA polymerase (RdRP). It is the major enzyme of viral RNA 
replication. It is, like most HCV proteins, post-translationally associated to the ER or ER-
derived membranes with its C-terminal hydrophobic tail of 21 aa (Ivashkina et al. 2002). 
NS5B shows structural similarities to other polymerases, a right hand structure with palm, 
finger and thumb domains (Lesburg et al. 1999). The palm domain represents the active site 
of the polymerase, fingers and thumb modulate RNA interactions. NS5B interacts with NS4B 
and NS5A (as described above) as well as NS3. 
1.4 HCV life cycle 
1.4.1 Binding and cell entry 
 
The process of HCV entry is not yet understood. One can assume that multiple interaction 
between viral and target cell components lead to virus particle attachment and 
internalization. A number of possible receptors could be identified. CD81 from the tetraspanin 
family was shown to bind envelope glycoprotein E2 with its large extracellular loop (Pileri et 
al. 1998). However, CD81 is expressed in many different cell types which makes it unlikely 
that HCV entry into hepatocytes is dependent on this receptor only. Experiments using HCV 
pseudo particles (HCVpp) also revealed that HCV entry can be inhibited by antibodies 
against CD81 after attachment to target cells. It is suggested that CD81 functions as a co-
receptor in a later step post-attachment (Cormier et al. 2004). Another potential receptor 
involved in HCV entry is the scavenger receptor class B type I (SR-BI). This receptor is 
highly expressed in hepatocytes mediating cholesterol uptake from lipoproteins. SR-BI also 
interacts with HCV E2 (Scarselli et al. 2002). Furthermore, E2 is reported to bind to C-type 
mannose-binding lectins DC-SIGN and L-SIGN as well as to the LDL-receptor (Cocquerel et 
al. 2006). Following attachment HCV entry is proposed to be internalized by receptor-
mediated endocytosis (Lindenbach et al. 2007).  
1.4.2 RNA translation 
 
After HCV cell entry, viral RNA is release into the cytoplasm. The positive sense ssRNA 
serves as mRNA for protein synthesis. As described above HCV genome lacks a 5’-cap 
structure. Translation is initiated cap-independent by the IRES located in the 5’-NTR. IRES 
domain III binds directly to the 40S ribosomal subunit and the initiating factor eIF3. Thereby 
the AUG start codon, which is located within IRES at the beginning of the core region (nt 
342), is placed directly on the P position (peptidyl site) of the ribosome and translation is 
initiated without recruiting other initiation factors as eIF4, eIF4B etc (Tsukiyama-Kohara et al. 




1992). The complex structure of the IRES is important for correct location of the start codon 
to the 40S ribosomal subunit. It induces conformational changes within the ribosomal subunit 
closing the mRNA binding cleft which leads to an exact positioning of the AUG codon (Spahn 
et al. 2001). Hydrolysis of GTP and recruitment of the 60S subunit leads to an active 
translation complex. IRES-dependent translation can be inhibited by nt 428-442 of the core 
region by RNA-RNA interaction with nt 24-38 in domain I of the 5’NTR. This product inhibition 
might play a role in regulation of the virus life cycle, especially the rate of translation versus 
replication (Kim, YK et al. 2003). 
1.4.3 RNA replication 
 
HCV RNA replication depends on a membrane-associated replication complex. NS4B 
induces membrane alterations forming vesicles likely derived from the rough ER or 
intracellular lipid rafts (Bartenschlager et al. 2004). This so-called membranous web is 
indicated to form the replication complex as HCV proteins are shown to accumulate on these 
structures (Egger et al. 2002). NS3hel and NS5B RdRP most likely play the central role in 
HCV RNA replication as subgenomic replicons which only express NS3 and NS5B are able 
to replicate (Lohmann et al. 1999). NS3hel is able to unwind duplex RNA and DNA as well as 
RNA/DNA duplexes in 3’ to 5’ direction. Its role in replication is not yet understood. It might 
play a role in initiation of replication and elongation by unwinding duplexes. NS5B as RdRP 
is assumed to serve as the catalytic centre in HCV RNA replication (Bartenschlager et al. 
2004). Positive-stranded RNA serves as a template of synthesis of negative-stranded RNA. 
Negative stranded RNA serves as template for positive strands RNA. It remains partially or 
fully double-stranded as replicative intermediates (RI) or replicative forms (RF) which serve 
as templates for semi-conservative, but asymmetrical RNA synthesis. Transcription leads to 
an almost ten-fold excess of positive-strands over negative-strands. Positive strands are 
used for translation or viral assembly (Bartenschlager et al. 2004).  
1.4.4 Virus assembly and release 
 
HCV particle assembly is not completely understood to date. It is likely that HCV particles 
integrate into ER membranes and get released over the secretory pathway. Recent studies 
hypothesized that HVC proteins E1, E2, p7, NS2, NS3 and NS5A are involved in virus 
particle assembly. Interactions between core and lipid droplets (LDs) were shown to be 
important as an initiating step in the assembly process (Boulant et al. 2007). A major role in 
assembly has been reported for NS5A. It is observed to co-localize with core on the surface 
of lipid droplets. Domain DI of NS5A was shown to interact with LDs which is crucial for virion 
production (Tellinghuisen et al. 2008). It  is suggested that NS5A enables interactions 




between core and LDs building the scaffold for the assembly pathway. It is described to 
influence assembly by regulation of replication by uncoupling viral proteins from replication 
(Tellinghuisen et al. 2008). Furthermore, Stapleford and Lindenbach (2011) revealed that 
NS2 physically interacts with E1-E2 and NS3. It might play a central role in organizing a 
complex essential for virus particle assembly coordinating E1-E2 interaction with NS3. 
However, earlier studies assumed NS2 playing a role in a post-assembly step forming fully 
infectious viral particles (Jones, DM and McLauchlan 2010). Ion channel p7 seems to be also 
involved in assembly acting within the assembly complex (Steinmann et al. 2007). NS3 was 
also described to be involved in particle assembly, but its role remains unclear.  
 
 
Figure 8  HCV life cycle. (A) Model of life cycle. Constructed with the help of Lindenbach and Rice (2005) p. 934. (B) 
Mechanism of RNA replication. Positive stranded RNA serves as a template for negative strands. Negative strands remain 
partially or fully double stranded (RF or RI) and serve as templates for semi-conservative but asymmetrical RNA synthesis 









1.4.5 HCV cell culture and replicon systems 
 
After its identification in the late 1980’s advances in HCV research was held back by the lack 
of a cell culture model which allowed studying HCV infection in vitro. In 2000 the group of 
Charles Rice reported the first efficient cell culture system to study HCV replication. Adaptive 
mutations in NS5A and in the hepatoma cell line Huh 7 were required for HCV replication in 
vitro (Blight et al. 2000). These findings marked a major step in HCV research. Later on, in 
2003, the group of Takaji Wakita discovered the genotype 2a isolate JFH-1 from a patient 
with fulminant hepatitis (Kato et al. 2003). The complete virus cell cycle can be studied with 
this isolate. It was shown that it is able to replicate, assemble and release infectious viral 
particle in Huh7 and Huh7.5 (a variation of Huh7 cells with more adaptive mutations) cells 
(Kato et al. 2003). These developments allowed new results in HCV research. But many 






















1.5 Aim of this thesis 
 
The goal of the project was to determine NS3 helicase involvement in HCV virus particle 
assembly. It should be identified which regions in NS3hel contribute to virion assembly. 
Residues in all three NS3hel domains were screened by mutational analysis for their ability 
of releasing infectious virus particles. To identify determinants within NS3 that are important 
for virus assembly a structure-based alanine-scanning mutagenesis of NS3 was performed. 
As it is suggested that NS3 contributes to virus assembly through its interaction with NS2, 
surface residues were targeted. Well conserved sites were in the focus as virus assembly is 
an important step in the viral life cycle. As we just wanted to scan for problems in virus 
assembly, residues that are known to be essential for serine protease activity, helicase 
activity or viral genome replication were avoided. Because miss-folding of NS3 should also 
be avoided structural considerations, like surface charges and hydrogen bonds should not be 
changed as well. Altogether, surface residues in well conserved sites which are non-
essential and structurally flexible were good candidates to be involved in particle assembly. 
25 mutations within NS3hel that met these criteria were chosen to be scanned in this study.  
Furthermore, NS3hel sites essential for replication were also scanned. To examine if 
mutations of the chosen residues influence particle assembly, constructs were screened for 
replication and infectivity. Therefore passaging experiments with the HCV cell culture system 
were performed using full length Jc1 replicons and Huh 7.5 cells.  
Constructs that were shown to replicate but not to produce infectious viral particles were of 
special interest for further studies. After confirming a defect in infectivity, these mutants were 
used to determine whether these residues are involved in viral assembly or release. 
Therefore, viral RNA within cell culture medium was monitored and intracellular particles 
were checked for infectivity. 
It was also determined whether the identified residues are involved in interactions with NS2 
playing a role in formation or stability of a newly described complex essential for virus particle 
assembly. Therefore, a protein-complex affinity purification system using streptavidin 
magnetic beads was used to capture NS2-NS3 interactions. 
Altogether, in this study NS3 helicase domain was screened to identify regions essential for 
replication and infectivity. The involvement of NS3hel in particle assembly and its 
involvement in protein-protein interactions were further studied.  
 
 




2 Material and Methods 
 
2.1 Material 
2.1.1 Cell lines and strains 
 
All cell lines were maintained in Dulbecco's modified Eagle medium (DMEM) (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal calf serum (FCS) (HyClone, Logan, UT) and 1 
mM nonessential amino acids (Invitrogen, Carlsbad, CA) at 37°C with 5% CO2. 
2.1.1.1 Huh7.5 cells 
 
Huh7.5 cells are a highly permissive cell line of human hepatoma cells. This subline was 
developed from a Huh7 cell line harboring self-replicating subgenomic HCV replicons and 
being cured of HCV by prolonged treatment with INF-α by the Rice laboratory. Huh7.5 cells 
obtain a cellular environment that is highly permissive for HCV replication (Blight et al. 2002).  
2.1.1.2 Huh7.5/BirA cells 
 
Huh7.5/BirA cells expressed the E.coli biotin ligase BirA. Cells were generated by lentivirus 
introduction in the Lindenbach laboratory (Stapleford and Lindenbach 2011). 
2.1.1.3 E. coli  
 
DH5α™ is a well-known and versatile E. coli strain. The DH5α cell has mutations of 
φ80lacZΔM15 and lacks the laqIq gene, which allows blue-white color screening of 
transformants with X-gal.  
 
Strain Genotype Reference 
DH5α F'(Φ 80 (ΔlacZ) M15) Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 rk- mk+ 
supE44 thi-1 gyrA relA1 
www.catalog.takara-
bio.co 









2.1.2 Growth media and buffer 
 
All growth media - liquid or solid - were prepared with twofold deionized water (ddH2O) and 
autoclaved for 30 minutes at 121°C before use. The right pH-values were adjusted with HCl 
or NaOH. 
2.1.2.1 Media for Escherichia coli cultures 
 
 LB media (pH 7.0) 
10g  Bacto-Tryptone 
5g  Bacto-Yeast Extract 
10g  NaCl 
H2O to a final volume 1L 
 
Supplementary for LBAmp-Media: 100µg/ml Ampicillin  
 
 LB Plates (pH 7.0) 
10g  Bacto-Tryptone 
5g  Bacto-Yeast Extract 
10g  NaCl 
15g  Agar 
H2O  to a final volume 1L 
 
Supplementary for LBCarb-Media: 100µg/ml Carbencillin  
 
 SOB Medium (pH 7.0) 
20g  Bacto-Tryptone 
5g  Bacto-Yeast Extract 
0.5g  NaCl 
10ml  250 mM KCl 








2.1.2.2 Pulldown experiment & Western blot buffer 
 
 TBS 
20mM  Tris (pH 7.5) 




20mM  Tris, pH 7.5 
150mM  NaCl 
1%  Triton X-100 
Protein inhibitor 
 
 Protein sample buffer 
 50 mM Tris-HCl, pH 6.8 
2% sodium dodecylsulfate (SDS) 
0.1% bromophenol blue 
10% glycerol 
100 mM DTT 
 
 Transfer buffer 1x 
25mM  Tris base 
190mM  Glycine 
0.1%  SDS 
 
 1x SDS-Page running buffer (pH 8.3) 
25mM  Tris 
250mM  Glycine  









 PBS (pH 7.4) 
80g  NaCl 
2g  KCl 
2g  KH2PO4 
11.5g  Na2HPO4 




1x PBS to final volume 1L 
 
 5% milk 
400 ml  PBS-T 
20g  Non-fat dry milk 
 
 1x SDS sample buffer 
50mM  Tris HCl pH 6.8 
2%  SDS 
0.1%  Bromphenol blue  
10%  Glycerol  
100mM  DTT 
 
2.1.3 Antibodies 
2.1.3.1 Primary Antibodies 
 
Primary Antibody Raised in Dilution Source  
Anti-NS2 (clone 6H6) Mouse 1:5000 Rice Laboratory, Rockefeller 
University, New York, NY 
Anti-NS3 (clone 9G2) Mouse 1:5000 ViroGen Corporation, 
Watertown, MA 
Anti-NS5a (clone 9E10) Mouse 1:20000 ViroGen Corporation, 
Watertown, MA 
Table 3  Primary Antibodies 




2.1.3.2 Secondary Antibodies 
 
Secondary Antibody Raised in Dilution Source  
Anti-mouse HRP Goat 1:5000 Jackson ImmunoResearch 




Goat 1:1 Jackson ImmunoResearch 
Laboratories, Inc, West 
Groove, PA 





AflII New England Biolabs Inc, Ipswich, MA 
Bsp120I Fermentas Inc, Glen Burnie, MD 
ClaI New England Biolabs Inc, Ipswich, MA 
Mung Bean Nuclease New England Biolabs Inc, Ipswich, MA 
Proteinase K Ambion, Austin, TX 
Superase-In Ambion, Austin, TX 
T4 DNA-Ligase New England Biolabs Inc, Ipswich, MA 
T4 DNA-Polymerase New England Biolabs Inc, Ipswich, MA 
T7 RNA-Polymerase Epicentre Biotechnologies, Madison, WI 
XbaI New England Biolabs Inc, Ipswich, MA 





1x DMEM Invitrogen, Carlsbad, CA 
1x DPBS Invitrogen, Carlsbad, CA 
30% H2O2 HACH Company, Loveland, CO 




5.5ml 100x Non essential amino acids Invitrogen, Carlsbad, CA 
Acrylamide (40%) American Bioanalytical, Inc., Natic, MA 
Agar American Bioanalytical, Inc., Natic, MA 
Ammonium persulfat (APS) American Bioanalytical, Inc., Natic, MA 
Bacto Tryptone BD Biosciences, Franklin Lakes, NJ 
Bacto Yeast Extract BD Biosciences, Franklin Lakes, NJ 
Bromphenol blue  BD Biosciences, Franklin Lakes, NJ 
Chloroform American Bioanalytical, Inc., Natic, MA 
DMSO Invitrogen, Carlsbad, CA 
DTT American Bioanalytical, Inc., Natic, MA 
Ethanol American Bioanalytical, Inc., Natic, MA 
Ethidium Bromide Sigma-Aldrich Corp., St. Louis, MO 
Ethylenediaminetetraacetic acid (EDTA) American Bioanalytical, Inc., Natic, MA 
Fetal Calf Serum (lot# frf26747) HyClone, Logan, UT 
Glycerol  American Bioanalytical, Inc., Natic, MA 
Potassium chloride Baker Bioscience, Sanford, ME 
KH2PO4 Baker Bioscience, Sanford, ME 
L.M.P. Agarose Promega, Fitchburg, WI 
LE Agarose Promega, Fitchburg, WI 
Magnesium chloride J.T. Baker, Phillipsburg, NJ 
Methanol American Bioanalytical, Inc., Natic, MA 
Na2HPO4 American Bioanalytical, Inc., Natic, MA 
Non-fat dry milk American Bioanalytical, Inc., Natic, MA 
Phenol Roche, Basel, Switzerland 
Ponceau S DiaSys Ltd, Berkshire, UK 
Renilla 5x lysis buffer Promega, Fitchburg, WI 
Sodium acetate Baker Bioscience, Sanford, ME 
Sodium Cloride J.T. Baker, Phillipsburg, NJ 
Tetramethylethylendiamine (TEMED) Promega, Fitchburg, WI 
Tris base Roche, Basel, Switzerland 
Tris buffer QUIAGEN, Valencia, CA 




Triton X-100 Calbiochem, Merck, Darmstadt, Germany 
Trypsine EDTA 0,05% Invitrogen, Carlsbad, CA 
Tween-20 Sigma-Aldrich Corp., St. Louis, MO 
Dynabeads™ M-280 Invitrogen, Carlsbad, CA 





Gaussia Luciferase Kit New England Biolabs Inc, Ipswich, MA 
HiSpeed Plasmid Midi Kit QUIAGEN, Valencia, CA 
Immpact DAB Vector Labs, Burlingame, CA 
LightCycler RNA Amplification Kit Roche, Basel, Switzerland 
QIAprep Spin Miniprep Kit QUIAGEN, Valencia, CA 
QUI quick PCR purification Kit QUIAGEN, Valencia, CA 
RNAeasy Mini Kit QUIAGEN, Valencia, CA 
SuperSignal West Pico Western Blotting 
Kit  
Thermo Scientific, Rockford, IL 





15cm Cell culture dishes  BD Biosciences, Franklin Lakes, NJ 
6 Wells Cell culture plates  BD Biosciences, Franklin Lakes, NJ 
96 Wells Cell culture plates  BD Biosciences, Franklin Lakes, NJ 
Air Clean 600 PCR Workstation AirClean® Systems, Raleigh, NC 
Analytic balance METTLER TOLEDO, Columbus, OH 
Balance METTLER TOLEDO, Columbus, OH 
70µl nylon cell strainer BD Biosciences, Franklin Lakes, NJ 
Centrifudge  Beckman Coulter, Brea, CA 
Centrifuge 5415D  Eppendorf, Hamburg, Germany 




Centrifuge 5415R  Eppendorf, Hamburg, Germany 
Centro LB 960  Berthold, Oak Ridge, TN 
Digital Camera Sony, Tokyo, Japan 
Incubator 37°C Thermo Scientific, Rockford, IL 
LightCycler 480  Roche, Penzberg, Germany 
Nano Drop Spectrophotometer ND-100  Thermo Scientific; Delaware, USA 
Power Pac HV  BioRad, Hercules, CA 
Tetrad 2 ThermalCycler  BioRad, Hercules, CA 
Thermomixer R  Eppendorf, Hamburg, Germany 
UV-Illuminator Stratagene, Santa Clara, CA 
Long wave UV-box Bi-O-Vision Spectroline, Westbury, NY 
Vortex Mixer Fisher Scientific, Waltham, MA 
Iso Temp 110 Waterbath Fisher Scientific, Waltham, MA 
Allegra x-15R Centrifuge  Beckman Coulter, Brea, CA 
Nikon Eclipse TS100 inverted microscope Nikon, Tokyo, Japan 
96 well plate qRT-PCR Roche, Penzberg, Germany 
Nutator Artisan Scientific, Champaign, IL 
MagnaRack™ Invitrogen, Carlsbad, CA 
Bio Trace PVDF Membrane Pall Life Sciences, Port Washington, 
NY 
ECM 830 Electro Square Porator BTX Harvard Apparatus, Holliston, MA 
SterilGARD III Advance Hood The Baker Company, Sanford, ME 
Forma Series II Water-Jacketed CO2 Incubator 
HEPA Class 100 
Thermo Scientific, Rockford, IL 
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The Jc1 chimera is a construct made by inserting NS2 codons 30-217 of JFH1 into the 
pJ6/JFH1 chimeric genotype 2a HCV cDNA clone (Lindenbach Lab described in Phan et al. 
2009). pJ6/JFH1 is a hybrid of the core to NS2 region of J6 and the subgenomic replicon 
JFH1 (Jones, CT et al. 2007). Jc1 is capable of yielding 100-1000-fold higher yields than any 
of the other HCV replicons (Pietschmann et al. 2006). Figure 9 gives an overview of all used 
Jc1 constructs. 
 
Figure 9  Jc1 constructs. All used constructs are compared. All constructs are based on the full length replicon Jc1 which is 
a hybrid of J6 and JFH1. The part of J6 origin is marked purple and the JFH-1 part is marked blued. Position of the GLuc2A 
gene is shown highlighted grey. Mutations within GNN are marked by the red star and ∆core deletions are marked by red 
dots. Insertion of the biotin acceptor peptide is also shown; site of insertion is marked in black. 
 
2.2.1.1 Jc1/GLuc2 clones 
 
The used vector plasmid Jc1/GLuc2 was constructed by the Lindenbach laboratory. GLuc2A 
reporter gene was constructed by inserting a silent MluI site between p7 and NS2 by site 
directed mutagenesis. This site was used to insert the Gaussia princeps luciferase reporter 
gene and 21 codons of the foot-and-mouth-disease-virus (FMDV) 2A ‘autocleaving’ gene. 




200-500ng plasmid-DNA (constructs made by Rudolph K. Béran by site-directed 
mutagenesis; named pJRB) were digested with EcoRI-HF and BsrGI. Jc1 as vector was also 
digested with EcoRI and. Jc1 clones were named JGN3.  
 
 
Figure 10 Cloning of pJGN3. Plasmids Jc1 and JRB were digested with restriction enzymes in order to clone the NS3hel 
mutation into the full-length replicon Jc1. Enzymes used were EcoRI and BsrGI. Restriction sites and their positions are 
shown. Numbers of an enzyme’s total restriction sites within each plasmid are shown in brackets. Positions are counted 
according to the full-length replicon Jc1. Figure made with ApE after the respective plasmid’s sequence. 
 
Reaction components were assembled as follows: 
200-500ng DNA 
1µl NEB buffer 4 (10x) 




to 10µl H2O 
 
2.2.1.2 Jc1/bioNS2 clones 
 
Jc1/bioNS2 constructs were made by the Lindenbach laboratory by insertion of the biotin 
acceptor peptide (BAP). Oligos YO-315 and YO-316 were introduced into the MluI site 
(described above) of Jc1. 
 




Primary structure of BAP GLNDIFEAQKIEWHE 
Sequence of YO-315 5’CGCGCCGGGCCTGAACGACATCTTCGAG
GCCCAGAAGATCGAGTGGCACGGCGGCA
GCGGCGGCAGCGA-3’ 
Sequence of YO-316 5’CGCGTCGCTGCCGCCGCTGCCGCCGTGC
CACTCGATCTTCTGGGCCTCGAAGATGTCG
TTCAGGCCCGG-3’ 
Table 10 Sequence of BAP and Oligos YO-315 and YO-316 
 
200-500ng of JGN3 plasmid DNA and the Jc1/bioNS2 vector were digested with EcoRI and 
MluI.  
 
Figure 11 Cloning of Jc1/BioNS2 plasmids. Plasmids Jc1-BioNS2 and JGN3 were digested with restriction enzymes in order 
to clone the NS3hel mutation into the biotin acceptor peptide (BAP) tagged full length replicon Jc1-BioNS2. Restriction sites 
and their positions are shown. Number of an enzyme’s total restriction sites within each plasmid are shown in brackets. 
Positions are counted according to the full-length replicon Jc1. Figure made with ApE after the respective plasmid’s 
sequence. 
 
Reaction components were assembled as follows: 
200-500ng DNA 
1µl NEB buffer 3 (10x) 
0.1µl BSA (100x) 
0.2µl EcoRI-HF 
0.2µl MluI 
to 10µl H2O 




Reactions were incubated at 37°C for 4 hours. 
Fragments were separated by electrophoresis in a thin glass-slide gel, in 0.8%. Low melting 
point agarose in 1x TAE buffer. The gel was stained in ethidium bromide (EtBr). Bands were 
cut out on a long-wave UV box and 50µl T10E0.1 and 1µl 1M MgCl2 were added to each 
fragment. Fragments were melted for 2 to 5 minutes at 72°C. 




to 17µl H2O 
2µl 10x ligation buffer (New England Biolabs®) 
1µl T4 DNA ligase 
 
Ligations were done at room temperature anywhere from 10 minutes to a few hours or at 
16°C overnight.  
Ligations were briefly melted at 72°C and 10µl were used to transform competent bacteria. 
2.2.2 Plasmid transformation into E.coli 
 
The used cloning strain was DH5α. The plasmids Jc1 and JGN3 were introduced into an 
aliquot of 100µl competent cells by heat shock transformation. Therefore 10µl of the plasmid 
was added to the aliquot and incubated on ice for 30 minutes. Then the cells were heat 
shocked in a 42°C water bath for 45 seconds and cooled down on ice for 2 minutes. After 
adding 900µl SOB media to the DH5α/plasmid mix the cells were incubated at 37°C for 1 
hour while shaking. Afterwards the cells were pated on LBcarb plates. The plates were 
incubated at 37°C over night. 
 
2.2.3 Purification of Plasmid-DNA  
 
Transformed cells were picked from the LBcarb plates and incubated in 50ml liquid LBamp over 
night at 37°C. 
For confirmation of the right plasmids ‘QIAprep Spin Miniprep Kit’ was used. Isolated and 
purified plasmid-DNA was used for enzymatic digestion and run on a 0.8% agarose gel. 
For isolation and purification of E.coli plasmid DNA the ‘HiSpeed Plasmid Midi Kit’ was used. 
Purified plasmid-DNA was used for sequencing and further experiments. 
 




2.2.4 Sequencing  
 
All constructs were verified by DNA sequencing at the W.M. Keck Foundation Biotechnology 
Resource Center at Yale University following the facilities’ instructions.  
 
Name Region Orientation Sequence 
YO-0363 NS3 Reverse 5’-TCGACGGCTCCACACTTGCAC-3’ 
YO-0364 NS3 Forward 5‘-TGCTGAGGGGGACTTGGTAG-3’ 
YO-0365 NS3 Reverse 5‘-GCCGTAGCCAGCACAGTTAGTCTG-3’ 
YO-0366 NS3 Forward 5‘-CGATGAATGCCACGCTGTGGATGCT-3’ 
YO-0367 NS3 Reverse 5‘-GGGAGAGGAAGTGGGCGTCTA-3’ 
YO-0368 NS3 Forward 5‘-CCGTCAGGCTTAGAGCGTATTTCA-3’ 
YO-0369 NS3 Reverse 5‘-AGTGTTGACAATCCTGCGAGGTATT-3’ 
YO-0073 bioNS2 Reverse 5‘-TCCTTGCACACCGGCTTTA-3’ 
YO-0074 bioNS2 Forward 5‘-GCCGCATTTGAGGTAAGTGGTA-3’ 
YO-0075 bioNS2 Reverse 5‘-TTCAACGCCAGCACGGACCTGT-3’ 
YO-0076 bioNS2 Forward 5‘-TCCATAAGCAGGCGCAAAC-3’ 
Table 11 Primers used for Sequencing 
 
2.2.5 In vitro transcription 
 
20µg plasmid-DNA was used to linearize with XbaI to prepare transcription templates. 
 
The reaction components were assembled as follows: 
20µg DNA 
10µl NEB buffer 4 (10x) 
1µl BSA (100x) 
3µl XbaI 
to 100µl H2O 
 
The digestion was done over night in a 37°C water bath. 
5’ overhangs were chewed back with Mung bean nuclease. Therefore 2µl Mung bean 
nuclease was added to the reaction and incubated at room temperature for 15 minutes. 
The reaction was cleaned up by adding 5µl 10% SDS and 3µl Proteinase K (18 mg/ml) and 
incubated at 50°C for 30 minutes. 




Afterwards a Phenol/Chloroform Extraction was performed. Phenol/Chloroform (CHCl3) (1:1) 
was prepared by using Tris-buffered phenol. Phenol/CHCl3 was pre-warmed 15 to 30 
minutes before use. 
The linearized and cleaned DNA was mixed 1:1 with phenol/ CHCl3 and then vortexed and 
spined for 5 minutes at maximum speed. The top layer was removed and the extraction 
repeated once. 
The Phenol/Chloroform Extraction was followed by ethanol precipitation. Therefore 1/10 
volume RNA-grade 3M NaOAc (pH 5.2) and 3 volumes 100% ethanol (EtOH) were added. 
DNA was pelleted by spinning 10 minutes at 4°C at top speed. The supernatant was 
removed and the pellet was washed with 1ml 70% EtOH. DNA was resuspended in 20µl 
RNA-grade T10E0.1. 
 
For the in vitro transcription the master mix was assembled as follows: 
4µl 5x transcription buffer (Epicentre) 
2µl 100mM DTT 
3.8µl H2O 
4.8µl 25mM MgCl2 (Roche) 
2.4µl NTP mix (25mM of each NTP) 
0.4µl T7 RNAP (Epicentre), 50 U/µl 
0.6µl SUPERasin (Ambion) 
 
2µl of template was added last and incubated at 37°C for 1.5 hours. 
The reaction was cleaned up with the ‘RNAeasy mini kit’. The volume was adjusted to get 
100µl RNA/µl and 10µl were used for transfections. 
 
2.2.6 Cell culture methods 
2.2.6.1  General conditions 
 
All cell culture work was performed in a biosafety level 2+ cabinet licensed by the State of 
Connecticut Department of Public Health. All cells were grown in cell culture dishes (BD 
Biosciences) in a 5% CO2 air incubator at 37°C. 
Huh 7.5 cells (human hepatoma cell line) were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM) containing high glucose, sodium pyruvate and L-glutamine, 10% heat 
inactivated fetal calf serum (FCS) and 1% (100µM) nonessential amino acids. Cells were 
typically split 1:3 every three days. They were maintained in a sub-confluent state (~80% 








Figure 12 Huh 7.5 cells in different stages of growth after splitting. (A) Cells 1d after they were split. (B) 2d post splitting. 
Cells were around 40-60% confluent. (C) 3d after splitting. Cells were around 80% confluent. They were ready to split. 
 
To split cells media was aspirated and the cells were washed with Dulbecco’s PBS. 3ml 
trypsin per 15cm dish (P150) was added and incubated at 37°C for 5 minutes. An equal 
volume of media was added and cells were gently resuspended by pipetting, pooled and 
placed in a 50ml Falcon tube using a 70µm nylon cell strainer to maintain the best possible 
separation of the cells and avoid cell clumping. Cells were plated on new 15cm plates 1:3 in 
20ml media. 
BirA expressing Huh7.5 cells were made by lentivirus transduction by the Lindenbach 
Laboratory.  
 
2.2.6.2 Transfections  
 
Cells were transfected when around 80% confluent. Plates were washed and trypsinized as if 
they would normally be split (see 2.2.6.1) and collected in 50ml tubes. The cells for the 
transfection were centrifuged at 1200rpm at 4°C for 6 minutes. Then the media was 
aspirated without disturbing the pellet. 5ml transfection PBS (~4°C) was added to re-suspend 
the pellet and another 35ml transfection PBS was added afterwards. The cells were 
centrifuged again at 1200rpm at 4°C for 6 minutes. Before the centrifugation 10µl of the cell 
suspension were removed for cell count. Therefore an equal volume of tryptan blue (dilution 
factor 2) to stain dead cells was added to the cell suspension. A hemocytometer was used to 
count the average cell count per quadrant under the light microscope. The hematocytometer 
volume of each quadrant is 0.1µl. The total number of cells was determined with the following 
equation: 
 
(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 𝑝𝑒𝑟 𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡) × (1 × 104 ) × 2 × (𝑚𝑙 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠) = 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 
 




After the second centrifugation PBS was aspirated, the cells were re-suspended in 5ml 
transfection PBS and then 35ml of PBS was added as described. After another centrifugation 
at 1200rpm at 4°C PBS was aspirated again and the cells were re-suspended to a volume 
needed to yield 2x107 cells/ml: 
 
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
2 × 107 
= 𝑚𝑙 𝑃𝐵𝑆 𝑡𝑜 𝑎𝑑𝑑 𝑡𝑜 𝑔𝑒𝑡 𝑎 𝑦𝑖𝑒𝑙𝑑 𝑜𝑓 2 × 107  
 
380µl cells with the appropriate yield were then electroporated with 1µg replicon RNA. For 
the electroporation a square-wave electroporator set with 5 pulses at 820V for 99µsec with a 
pause of 1.1 seconds between each pulse was used. 
After electroporating the cells rested for at least 10 minutes while still in the cuvettes. A 
sample of cells without adding RNA was always electroporated as a mock control. After the 
electroporated cells rested in the cuvettes and were added to 9.6ml pre-warmed (in a 37°C 
water bath) media and plated onto 10cm plates. The cells were incubated at 37°C. 
2.2.6.3 Passaging experiments 
 
Cells were passaged as described above every 3 days or when >80% confluent. Cell culture 
medium of the transfected cells was collected at various time points post-electroporation. 
Medium was clarified of cells by centrifugation at 3000rpm for 5 minutes.  
 
Figure 13 Passaging experiments. Huh7.5 Cells were electroporated with JGN3-RNA and plated on 10 cm dishes. When cells 
were about 80% confluent (about every 3 days) cell culture supernatant was harvested and the cells were passaged. The 
harvested supernatants were used for further analysis and were stored at -80°C. 
 
 




2.2.6.4 GLuc activity/Luciferase assay 
 
For determination of replication a Gaussia Luciferase (GLuc) assay was performed with the 
BioLux™ Gaussia Luciferase Kit. GLuc from the marine copepod Gaussia princeps is a 
reliable reporter to monitor gene-expression and replication via bioluminescence. FMDV 2A 
peptide mediates autocleavage of the protein at the GLuc2A/NS2 site. 
 
 
Figure 14 GLuc is a sensitive reporter for virus replication and infectivity. Scheme of the HCV polyprotein and polyprotein 
processing with the GLuc 2A insertion.  Signal peptidase cleavage site is shown by filled arrowheads, signal peptide 
peptidase cleavage sites by open arrowheads, the FMDV 2A autocleavage site is indicated by a filled star, NS2-NS3 cysteine 
autoprotease cleavage by an open circle and NS3-NS4A serine protease cleavage sites by filled arrowheads. 
 
The used Jc1 replicons contain the GLuc gene. GLuc is expressed by the cells during the 
replication process and secreted to the cell culture supernatant. The luciferase catalyses an 
ATP-independent oxidation of the substrate coelenterazine. This reaction emits light (New 
England Biolabs 2011; Wiles et al. 2005; Tannous et al. 2005). 
 
Figure 15 Luciferase catalyzed oxidation of Coelenterazine (New England Biolabs 2011). Luciferase was expressed and 
secreted by Jc1 transfected Huh 7.5 cells. In order to monitor replication luciferase activity was measured with the 
luminescent plate reader. Therefore a coelenterazine-buffer-mix was added to the sample. Secreted luciferase in cell 
culture supernatants react with coelenterazine which emits light at 475 nm. This can be measured by the luminescent plate 
reader. 
 
80µl of collected cell culture medium was mixed with 20µl of Renilla 5x lysis buffer (Promega; 
Wisconsin, USA) in order to eliminate infectivity. 20µl of this sample was used for GLuc 
activity measurement. BioLux™ GLuc Substrate was mixed 1:100 with BioLux™ GLuc Assay 
Buffer. On a Centro LB 960 luminescent plate reader (Berthold) the sample was injected with 
50µl Gaussia luciferase assay reagent (New England Biolabs 2011) and measured with an 
integration time of 10s. 





Figure 16 BioLux™ GLuc Assay (New England Biolabs 2011). First, substrate and buffer were mixed 1:100. 20µ of each 
sample was used per well. 50µl substrate-buffer-mix were delivered to each well and the measurement was done with a 




For measuring infectivity of the different constructs, 20µl of the supernatants harvested at 
various time points were used to infect native Huh 7.5 cells. Therefore, native cells were 
seeded at 6.4 × 103 cells/well in 80µl media one day prior of the infectivity assay. Each well 
was coated with 30µl Poly-L-lysine hydrobromide diluted to 100µg/ml in ddH2O. 
After a 24h absorption period the cells were washed three times with Dulbecco’s PBS and 
100µl media was added. The cells were incubated at 37°C for another 48h. Afterwards media 
was collected and a Luciferase assay was performed as described above.  
2.2.6.6 Intracellular Infectivity 
 
To measure intracellular infectivity cells were harvested 48h post-transfection by 
trypsinization followed by centrifugation at 1200rpm for 5 minutes. The cells were 
resuspended in a small volume of complete media and snap-frozen in liquid nitrogen. In 
order to disrupt the cells three rounds of thawing (37°C) and refreezing in liquid nitrogen  




(-196°C) were performed. Cellular debris was removed by centrifugation at 3000rpm for 5 
minutes. The supernatants were tested for infectivity as described above.  
2.2.6.7 Anti-NS5a staining of HCV-infected Huh 7.5 cells 
 
In order to measure infectivity besides the Luciferase assay anti-NS5a staining was used. 
Therefore 72h post-infection media was removed from the plates with the infected cells and 
washed with1xPBS. To fix the cells PBS was replaced by ice-cold methanol and incubated in 
the -20°C freezer for 20 minutes to several days. Afterwards, the cells do not contain 
infectious material any more. Methanol got dumped off and the plates were air-dried for at 
least 10 minutes until completely dry. Then the plates were washed twice with 1xPBS and 
endogenous peroxidase was blocked by adding 1xPBS containing 3% H2O2 for 5 minutes at 
room temperature. The plates were washed twice again with 1xPBS and blocking buffer was 
added. The plates were blocked for 30 minutes with gently rocking at room temperature. The 
blocking buffer was replaced by PBS-T containing a 1:20000 dilution of anti-NS5a 
monoclonal antibody 9E10. The plates were incubated 1 hour at room temperature with 
gentle rocking and washed twice with 1xPBS afterwards. The secondary antibody (ImmPress 
anti-mouse-HRP) was diluted two-fold in 1xPBS-T, added to the plates and incubated for 30 
minutes at room temperature with gentle rocking. Then the plates were washed twice with 
1xPBS and once with 1xPST-T. In order to develop the plates Immpact DAB was used 
according to the manufactures instructions. The plates were incubated at room temperature 
for 1 to 10 minutes. The stained plates were analyzed using an inverted light microscope 
(Nikon).   
2.2.7 RNA extraction 
 
RNA extraction from harvested supernatants was performed using the ‘Quiagen viral RNA 
extraction kit’ after the manufacturer’s instructions. 
2.2.8 Quantitative RT-PCR 
 
Quantitative RT-PCR is a reliable and very sensitive method for detection and quantization of 
nucleic acids levels. The qRT-PCR machine is able to perform real time detection of PCR 
products as they accumulate during PCR cycles. 
For the detection of HCV positive strand RNA specific primers and minor groove binding 
(MGB) probe were used. Primers target a conserved region of the HCV 5’ untranslated 
region (UTR) from genotype 2a. 
 




Forward primer 5’-CTTCACGCAGAAAGCGTCTA-3’ 
Reverse primer 5’-CAAGCACCCTATCAGGCAGT-3’ 
Probe 5’-6FAM-TATGAGTGTCGTGCAGCCTC-MGBNFQ-3’ 
Table 12  Sequence of primers and probe used for RT-PCR 
 
The specific probe is label with the fluorescent reporter dye 6-Carboxyflourescein (6-FAM) at 
the 5’ end and the minor groove binding non-fluorescent quencher (MGBNFQ) at the 3’ end. 
In an intact probe the reporter dye emission is quenched by the non-fluorescent quencher. 
During each PCR cycle the DNA polymerase cleaves the 5’ reporter dye from the probe 
through its 5’-3’ nuclease activity. The reporter dye gets released and emits its characteristic 
fluorescence. The change in the emitted fluorescence correlates with the amount of PCR 
product produced.  
 
Figure 17 Scheme of RT-PCR reaction.  





Quantitative RT-PCR was performed by using the LightCycler RNA Amplification Kit with the 
Roche LightCycler 480. All mixing was performed in an Air Clean 600 PCR Workstation. 
The master mix was prepared as follows: 
7.55µl Nuclease-free water 
4µl  Reaction Mix 
4µl MgCl2 
0.75µl Forward Primer 
0.75µl Reverse Primer 
0.5µl Probe 
0.4µl Enzyme Mix 
0.05µl RNase Inhibitor 
 
A 1:10 dilution series of the standard was made to create determinants ranging from 4 ×
107copies per reaction to 4 × 100 copies per reaction.  
2µl of HCV standard, unknown sample or no template control were added to 18µl of the 
master mix in the qRT-PCR 96 well plate. After loading the master mix and samples a 
sealing foil cover was placed on the plate and the plate was spun at 1000rpm for a few 
minutes. The plate was placed in the Roche LightCycler 480 using the following cycle 
conditions: 
 
FastTaq Trial Temperature (°C) Hold Ramp Rate (°C) 
RT 56 45min 4.4 
Denaturation 95 5min 4.4 
PCR (50 cycles) 95 10sec 4.4 
 60 20sec 2.2 
 72 3sec 4.4 










2.2.9 Pulldown experiments 
 
For these experiments Jc1 constructs expressing biotin acceptor peptide (BAP) at the amino-
terminal end of NS2 were used to determine physical interactions between proteins important 
for virus assembly. Huh 7.5 cells which express the E.coli biotin ligase BirA were transfected 
with Jc1/bioNS2 RNA.  
Expression of biotin AP-tagged proteins in the presence of E.coli biotin ligase BirA results in 




Figure 18 Biotinylation of the biotin acceptor peptide (BAP) catalyzed by E.coli BirA. 
For isolation of biotinylated proteins Streptavidin-coupled Dynabeads™ M-280 were used. 
Streptavidin binds biotin molecules with high affinity. Biotinylated proteins get bound to the 
magnetic beads. The beads can get isolated with magnetic forces using a magnetic rack and 
proteins can be purified from total cell lysates. 
48h post-transfection the cells were washed with 1x PBS and trypsinized. Cells were 
harvested and centrifuged at 1200rpm at 4°C for 6 minutes. Afterwards cells were washed 
twice with 5ml PBS. Then the cells were resuspended in 1ml TBS-Tx and put on ice for 30 
minutes to completely lyse the cells.  
The lysate was spun in a microfuge at 13,000rpm at 4°C for 5 minutes to remove cellular 
debris. The supernatant was collected and placed in a fresh 2ml tube. 20µl of the lysate was 
stored at -80°C as the total contents control sample for later experiments.  
To remainder of lysate 50µl of prewashed streptavidin magnetic beads were added. Per 
sample 50µl beads were prewashed with 167µl buffer TBS-Tx on a nutator at 4°C for 30min. 




Supernatant was removed and the beads were resuspended in 50µl TBS-Tx per sample. The 
lysate/magnetic beads mix was incubated on the nutator at 4°C for 1h. Afterwards the mix 
was separated on a magnetic tube rack (MagnaRack). The supernatant was removed and 
1ml TBS-Tx was added to the samples and nutated for another 15min. This washing step 
was repeated two more times.  
Then 100µl of protein sample was added and samples were heated to 94°C for 10min. 
Samples were spun briefly and placed on the MagnaRack to separate proteins from 
magnetic beads. Supernatants were removed. An equal volume of protein sample buffer was 
added to these supernatants and to the controls. Controls were heated to 94°C for 10 
minutes as well and all samples were separated by sodium dodecylsulfate polyacrylamide 
electrophoresis (SDS-PAGE) on a 12% SDS-PAGE gel and transferred to PVDF 
membranes.  
 














2.2.10 Western blot 
 
Western blot was performed after standard methods. Samples were prepared in protein 
sample buffer, separated on a 12% SDS-PAGE gel as described above.  
Proteins were transferred to a PVDF membrane in transfer buffer running at 110V for 1h. The 
membrane was blocked in blocking buffer (5% milk) for 1h at RT or overnight at 4°C. Then 
the membrane was probed with the antibody against NS2 diluted 1:5000 in blocking buffer 
for 1h at RT or at 4°C overnight. The membrane was washed a couple of times with PBS-T 
and incubated with the secondary anti-mouse antibody diluted 1:5000 in blocking buffer for 
1h followed by another couple of washes with PBS-T. For the development the SuperSignal 

























3.1 Confirmation of pJGN3 clones 
  
Genotypes of the Jc1/Gluc2 clones had to be confirmed first. Correct mutations in the 
NS3hel domain had to be verified. 
The correct insertion of the mutations was checked by digestion with restriction enzymes 
EcoRI and BsrGI. Fragments were separated on a 0.8% agarose gel and compared to the 
maternal pJRB restriction fragments as well as to the vector fragments (pJc1).  
 
Construct Expected size of  bigger 
fragment [kb] 
Expected size of smaller 
fragment [kb] 
JRB 7800 4564 
JGN3 8382 4564 
Jc1 8382 4564 
Figure 20  Agarose gel of restriction fragments. Expected size of the bigger fragments of pJGN3 is bigger than the one of 
pJRB. Smaller fragments are expected to be equal in size. Smaller fragments include the mutations. Expected fragment sizes 
of pJGN3 are equal to pJc1/Gluc2. 
 
All fragments appeared at the expected sizes in the agarose gel. 




In addition, the correct introduction of the NS3hel mutations was confirmed by sequencing 
the plasmids at the W.M. Keck Foundation Biotechnology Resource Center at Yale 
University.  
 
Figure 21  Verified NS3 sequences. The sequence of Jc1 is shown in top lines. Mutations are marked underlined and red. 
Numbers in each top line show positions within the NS3 region. Numbers are in bases. Numbering of the NS3 sequence is 
relative to the sequence of the NS3 region of full length replicon Jc1.  




In all 25 plasmids the mutations of interest were correctly inserted within the NS3hel domain 




All mutants were tested for their ability to replicate in cell culture. In order to study HCV virion 
assembly only those mutants showing the ability to efficiently replicate can be used for 
further studies. Furthermore one can learn about residues essential for replication within the 
NS3hel domain that were not mapped yet.  
3.2.1 Constructs with changes within NS3hel domain 3 
 
15 constructs with various alanine substitutions within the NS3 subdomain 3 were made by 
cloning. Four of them have changes within a well conserved protuberance at the side of 
domain 3 which projects from alpha helix 21. Three constructs contain alanine substitutions 
in a well conserved corner of domain 3 within alpha helix 20, another three in a well 
conserved acidic patch on the surface of domain 3 which projects from alpha helix 14. Two 
more mutants have changes in well conserved residues projecting from alpha helix 15 and 
three more constructs in a well conserved patch on the surface of domain 3, projecting from 
alpha helix 16 (see figure 22). 
 
 
Figure 22  Locations of mutations within NS3hel domain 3. (A) Ribbon model of NS3hel. Domain 1, domain 2 and domain 3 
are colored yellow, light blue and green. Substituted residues are highlighted red and marked by 1-letter-code residue 
name and position. (B) Surface model of NS3hel. Mutated residues are highlighted red. Models were rendered with PyMOL; 
Protein Data Bank code 3KQL was used.  
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Table 14 Changes within NS3hel domain 3.   
 
To determine replication of JGN3-constructs in the context of HCV full length replicon Jc1 in 
cell culture passaging experiments were performed on the basis of the Jc1/GLuc2 reporter 
system as described in ‘Materials and Methods’ (p. 37ff.) . Briefly, Huh 7.5 cells were 




transfected with RNA of the different mutants. Cells were split after 72h or when 
subconfluent. The GLuc gene and the FMDV auto-cleavage peptide 2A were encoded 
between p7 and NS2. GLuc2 was secreted into the cell culture medium of Huh 7.5 
transfected cells reporting replication activity as GLuc activity could be measured over time. 
Cell culture media was harvested every 24h and GLuc activity was measured as described in 
Material and Methods. Functionality and sensitivity of this system were described earlier by 
Phan et al. (2009). As a control the polymerase defective construct Jc1/GLuc2(GNN) was 
used to compare values to a construct that is known to be unable to replicate as it lacks 
polymerase activity. Jc1/GLuc2(∆core) was used to monitor a construct which is able to 
replicate but unable to produce infectious virus as it lacks the core region. Jc1/GLuc2(∆core) 
shows around 10 fold lower levels of secreted GLuc activity than WT values due to its defect 
in production of infectious virus particles which makes it unable to spread within the cell 
population. Furthermore wild-type Jc1/GLuc2 (WT) and mock controls were used.  
3.2.1.1 Replication of constructs with changes within NS3hel domain 3 alpha helix 20 and 21 
 
As expected, WT Jc1/GLuc2 efficiently replicated. Measured GLuc activity representing 
replication was 5.7x104 RLU after 24 hours post-transfection rising to 2.4x106 RLU after 48 
hours to 9.6x108 RLU and 6.8x107 RLU at 72 hour and 96 hour time points. 
Jc1/GLuc2(∆core)  also replicated but showed, as described above, more than 10 fold lower 
GLuc activity levels than WT. Polymerase defective Jc1/GLuc2(GNN) as well as mock 
control did not replicate. Mock GLuc levels remained around 2x103 RLU at all time points. 
Jc1/GLuc2(GNN) GLuc activities stagnated around 4x104 RLU during all measured time 
points post-transfection.  
Within  α-helix 20 and 21 of NS3hel domain 3 three JGN3 constructs – JGN3-2, JGN3-3 and 
JGN3-5 – showed GLuc activity levels comparable to WT levels at 24h, 48h, 72h as well as 
96h post-transfection indication efficient replication. Mutations T612A and H613A (JGN3-2) 
had no impact on replication. Measured GLuc levels were similar to WT values at each time 
point. GLuc activities got up from 2.8x104 RLU 24h post-transfection to top values of 2.6x107 
and 8.6x107 RLU at 72h and 96h time-points. Alanine substitutions P614A and K617A 
(JGN3-3) did not influence replication either. Measured GLuc activity 24 hours post-
transfection was 1.3x106 RLU rising to 6.4x107 RLU and 2.7x108 RLU 72 and 96 hours post-
transfection. Phenotype of mutations L588A, K589A, P590A and T591A together (JGN-5) 
was also similar to WT Jc1/GLuc2 with values of 6.3x107 RLU and 3.9x107 RLU at 72 and 96 
hour time points. 
Mutations T612A, H613A, P614A, K617A and Y618A within the well conserved protuberance 
of α-helix 21 lead when combined (JGN3-1) to a severely defect in replication. Values ranged 
between 4x104 and 2.7x105 RLU, around 1000 fold lower than WT GLuc activities.  




Furthermore, constructs JGN3-4, JGN3-5 and JGN3-7 showed reduced GLuc activities 
compared to WT. Single mutation Y618A (JGN-4) influenced replication. Values at 72 hours 
and 96 hours were with 2.1x106 and 4.4x106 RLU around 10 to 100 fold lower than WT 
measurements. Isolated mutations L588A with K589A (JGN-6) enhance GLuc activity from 
1.4x105 at 24 hours post-transfection to 9.3x106 RLU at 48 hours post-transfection. 
Replication activity drops to 1.4x106 and 3.5x105 RLU at later time points 72 and 96 hours 
post-transfection. Mutations P590A and T591A (JGN-7) showed to increase GLuc activity 
from 4.4x104 to 5.9x106 RLU from 24 hours to 96 hours post-transfection. But GLuc levels 
were around 10 fold lower than WT levels. 
 
Figure 23  Replication of JGN3 constructs with changes in alpha helices 20 and 21 of domain 3. Cells were transfected with 
described mutants and controls. Medium was collected 24h, 48h, 72h and 96h post-transfection. Data represents secreted 
GLuc activity over time in Relative Light Units (RLU). Wild-type Jc1 (WT) is shown as a positive control. Further controls 
mock, GNN and ∆core (described above) are also shown. Values represent average measurements of at least two to three 
individual rounds of experiments. Error bars represent standard deviation of the mean. 
 
3.2.1.2 Replication of constructs with changes within NS3hel domain 3 alpha helix 14, 15 
and 16. 
 
Within α-helix 14, 15 and 16 of NS3hel domain 3 five constructs – JGN3-8, JGN3-9, JGN3-
10, JGN3-12 and JGN3-15 – efficiently replicated showing GLuc activities alike WT. 
Combined mutations D503A, E508A and R512A within the acidic patch and α-helix 14 (JGN-
8) were able to replicate like WT. GLuc activity levels raised from 6.4x105 RLU after 24 hours 
to 8.3x106 and 5.9x107 RLU 72 and 96 hours post-transfection. Mutation D503A within an 











































































































activities reached 4x108 and 2.2x108 RLU 72 and 96 hours post-transfection. Furthermore, 
substitutions E508A and R512A (JGN-10) within α-helix 14 were not implicated in replication. 
GLuc activity was 7.5x106 RLU and 3x107 RLU at the 72h and 96 hour measurements. 
Constructs including upstream mutations T537A, T540A and H541A (JGN-12) showed ability 
to replicate. GLuc activity elevated from 3.9x104 RLU 24 hours post-transfection to 3.5x107 
and 2.9x107 RLU 72 and 96 hours post-transfection. Constructs with mutations S548A and 
Q552A (JGN-15) within this α-helix were also able to replicate. Values were 1.5x107 and 
2.1x107 RLU at both time points 72 and 96h.  
Remaining three constructs within α-helix 14, 15 and 16 – JGN3-11, JGN3-14 and JGN3-14 
– of NS3hel domain 3 revealed significantly low GLuc levels showing severe defects in 
replication. Within α-helix 15 mutation E530A combined with E533A (JGN-11) severely 
reduced replication. GLuc activity did not exceed 1.6x105 RLU. Time points 24h, 72h and 96 
hours remained 3.5x104, 5x104 and 3.5x104 RLU. Alanine substitutions of residues D543 and 
H545 (JGN-14) within α-helix 16 also reduced replication. Measured RLU levels did not rise 
over 1.2x105 RLU at all time points. Combination of the four mutations D543A, H545A, 
S548A and Q552A within α-helix 16 (JGN-13) lead to severely reduced replication with GLuc 
levels less than 4.6x105 RLU.  
 
Figure 24  Replication of JGN3 constructs with changes in alpha helices 14, 15 and 16 of domain 3. Cells were transfected 
with described mutants and controls. Medium was collected 24h, 48h, 72h and 96h post-transfection. Data represents 
secreted GLuc activity over time in Relative Light Units (RLU). Wild-type Jc1 (WT) is shown as a positive control. Further 
controls mock, GNN and ∆core (described above) are also shown. Values represent average measurements of at least two 
to three individual rounds of experiments. Error bars represent standard deviation of the mean. 
Within NS3 helicase domain 3 a total of eight JGN3 mutants were able to replicate as 
efficient as WT. Four constructs showed severely defects in replication. The remaining three 
mutants showed reduced replication capacity.   




Results reveal that α-helices 15, 16, 20 and 21 play a role in viral replication. Whereas 
scanned residues within α-helix 14 as well as the acidic path between α-helices 13 and 14 do 
not seem to influence replication. 
3.2.2 Constructs with changes within NS3hel domain 2 
 
Within NS3hel domain 2 seven residues implicated in flavivirus assembly were substituted. 
Four of the changes are located within β sheet E1. Remaining three mutations are adjacent 
to this structure.  
Figure 25  Mutation locations in NS3hel domain 2. (A) Ribbon model of NS3hel. Domain 1, domain 2 and domain 3 are 
colored yellow, lightblue and green. Substituted residues are highlighted red and marked by 1-letter-code residue name 
and position. (B) Surface model of NS3hel. Mutated residues are highlighted red. Models were rendered with PyMOL, 
Protein Data Bank code 3KQL. 
 


















Table 15 Changes within NS3hel domain 2. 




Replication was screened with the previously described system and mutants were compared 
to WT, mock, GNN and ∆core controls.  
Within NS3 helicase domain 2 four JGN3 mutants – JGN3-16, JGN3-17, JGN3-18 and 
JGN3-19 – showed significantly low levels of GLuc activity compared to WT GLuc activity. All 
four constructs showing severe defects in viral replication had changes within NS3hel 
domain 2 β-sheet E1. Construct JGN3-16 containing the combination of alanine substitutions 
E346A, P348A, F349A, Y350A and P355A showed a significantly reduced replication activity 
compared to the WT Jc1/GLuc2 phenotype. GLuc levels ranged between 5.1x104 and 
2.5x105 RLU. 72 and 96 hours post-transfection GLuc activity values were measured about 
1000 fold lower than the efficiently replicating WT. Separate mutations in the region of this 
beta sheet showed the same phenotype. Substitutions E346A and P348A (JGN3-17) as well 
as F349A and P355A (JGN3-18) revealed a defect in replication. JGN3-17 GLuc activities 
were 100 to 1000 fold lower than WT. Values around 1.5x105 RLU measured for JGN3-18 at 
72 and 96 hours post-transfection also showed a replication defect. Furthermore, single 
mutation Y350A in JGN3-19 also lead to significant reduction of viral replication. This data 
implies that this region has to be critical for replication.  
The remainder of mutants within domain 2 – JGN3-20 – showed a reduction of GLuc activity. 
Alanine substitutions of residues G342, R343 and E344 adjacent to beta sheet E1 did not 
reduce replication activity of JGN3-20. Measured values stagnated between 2.9x106 and 
9.1x106 RLU at 48 to 96 hour time points post-transfection. Results revealed that all scanned 
mutants with changes in NS3hel domain 2 influence viral replication. All of these constructs 
were located within beta sheet E1. Changes in adjacent residues reduced replication 
capacity. Data implicated that NS3 domain 2 is involved in viral replication as discussed later. 
 





Figure 26 Replication of JGN3 constructs with changes in domain 2. Cells were transfected with described mutants and 
medium was collected 24h, 48h, 72h and 96h post-transfection. Data represents secreted GLuc activity over time. Wild-type 
Jc1 (WT) is shown as a positive control. Further controls mock, GNN and ∆core (described above) are also shown. Results 
represent at two to three individual rounds of experiments. Error bars represent standard deviation of the mean. 
 
3.2.3 Constructs with changes within NS3hel domain 1 
 
Within Domain 1 four amino acid substitutions were made in a conserved surface on the 
‘back’ of domain 1, projecting from alpha helix 8. Another four residues were changed in 
areas which were implicated in HCV assembly located within domain 1. 
Figure 27  Mutation locations in NS3hel domain 2. (A) Ribbon model of NS3hel. Domain 1, domain 2 and domain 3 are 
colored yellow, lightblue and green. Substituted residues are highlighted red and marked by 1-letter-code residue name 
and position. (B) Surface model of NS3hel. Mutated residues are highlighted red. Models were rendered with PyMOL, 

















































Conserved surface on back of domain 1, 










Table 16 Changes within NS3hel domain 1. 
 
Replication was screened with the previously described system and mutants were compared 
to WT, mock, GNN and ∆core controls as in the other domains.  
Within NS3 helicase domain 1 four of the five studied mutants – JGN3-21, JGN3-22, JGN3-
23 and JGN3-25 – were significantly influenced in replication. Changes of residues D308, 
Q309, E311A and D312A within α-helix 8 (JGN3-21) lead to reduced GLuc activities 
compared to WT. GLuc activities of 4.5x106, 6.6x105 and 4.1x105 RLU at 48, 72 and 96 
hours post-transfection were around 100 fold lower than WT. Combination of mutations 
D308A and Q309A as included in JGN3-22 also showed reduced GLuc activities. Values 
were 2.2x105, 1.5x105 and 2.3x105 RLU after 48, 72 and 96 hour time points. Combination of 
mutations E311A and E312A, as scanned with JGN3-23 also significantly reduced GLuc 
activities. Values did not exceed 3.1x105 RLU at all time points. Furthermore, combined 
mutations A217R, Q221A, G222A and Y223A (JGN3-25) severely reduced replication as 
well. GLuc activity was below 5.9x104 RLU at all time points post-transfection. 
Construct JGN3-24 which includes the A217R mutation was able to replicate efficiently. 
GLuc activity levels of 2.6x107 and 1.8x107 RLU 72 and 96 hours post-transfection were alike 
WT values. 
Within NS3hel domain 1 all studied changes within alpha helix 8 lead to defects in replication 
as well as the mutant with changes around mutation Q221A. Data implicates that these 
regions are important for viral replication. One scanned mutant efficiently replicated similar to 
WT phenotype. 





Figure 28 Replication of JGN3 constructs with changes in domain 1. Cells were transfected with described mutants and 
medium was collected 24h, 48h, 72h and 96h post-transfection. Data represents secreted GLuc activity over time. Wild-type 
Jc1 (WT) is shown as a positive control. Further controls mock, GNN and ∆core (described above) are also shown. Results 
represent at two to three individual rounds of experiments. Error bars represent standard deviation of the mean. 
 
3.2.4 Summary of replication results 
 
Replication experiments revealed some residues and some region within NS3hel domains 
which are important for viral replication. In each domain of NS3hel, sites that influence 
replication could be determined. Regions within domain 1 and domain 2 were especially 
sensitive for changes. Out of 25 scanned constructs 9 replicated similar to WT. 12 constructs 
had severe defects in replication. The remainder of mutants showed reduced GLuc activity. 
Within domain 2 beta sheet E1 was shown to play a role in viral replication. Alpha helix 8 of 
domain 1 was also sensitive for changes. Within domain 3 alpha helices 15, 16, 20 and 21 




Mutants were also screened for infectivity. All constructs were monitored by infecting naïve 
Huh 7.5 cells with conditioned cell culture medium from the transfected cells collected at 
various time points. Following a 24h absorption period cells were washed and harvested in 
fresh medium. Secreted GLuc was measured 72h post-infection. WT was used as positive 


















































non-infectious controls. Jc1/GLuc2(∆core) containing a deletion of the core gene was used 
as a control which is able to replicate but does not produce infectious virus particles. 
Constructs with severe defects in replication are expected not to be infectious as they are 
unable to replicate.  
3.3.1 Constructs with changes within NS3hel domain 3 
 
From 15 constructs screened with changes in domain 3, four did not replicate (JGN3-1, 
JGN3-11, JGN3-13 and JGN3-14) and another three showed reduced replication (JGN3-4, 
JGN3-6 and JGN3-7). Remaining eight mutants replicated efficiently.  
As expected here WT Jc1/GLuc2 produced infectious virus. Measured GLuc activities rose 
from 1.9x104 RLU when infected with supernatants harvested 24 hours post-transfection to 
7.4x106, 3.2x107 and 2x107 RLU when infected with supernatants 48, 72 and 96 hours post-
transfection. Controls mock and GNN which did not replicate, were not infectious. GLuc 
activities were below 3x103 RLU. Jc1/GLuc2(∆core) with a deletion of the core gene which 
was able to replicate, showed GLuc activities below 3.1x103 RLU at all scanned time points. 
 
3.3.1.1 Infectivity of constructs with changes within NS3hel domain 3 alpha helix 20 and 21 
 
Within alpha helix 20 and 21 of NS3 helicase domain 3 constructs JGN3-2, JGN3-3 and 
JGN3-5 were able to replicate efficiently.  
JGN3-3 showed ability to infect naive Huh7.5 cells alike WT. GLuc activity levels reached 
4x106 and 1.4x107 RLU when infected with supernatants harvested 72 and 96 hours post-
transfection. JGN3-5 showed GLuc activity levels of 1.3x107 and 1.7x107 RLU using 
supernatant collected 72 and 96 hours post-transfection.  
Measured GLuc activities of mutant JGN3-2 were significantly lower than WT levels. GLuc 
activities stagnated between 1.9x104 and 2.4x104 RLU when infected with supernatants 
harvested 48, 72 and 96 hours post-transfection which is around 10000 fold lower than WT 
GLuc activity.  
Within alpha helix 20 and 21 of NS3hel domain 3 the construct that showed severe defects in 
replication (JGN3-1) showed significantly lower GLuc levels than WT. Values ranged 
between 2x103 and 1x104 RLU during all time points used to infect naïve Huh7.5 cells. 
Scanned mutants JGN3-4, JGN3-6 and JGN3-7 that showed reduced GLuc levels during 
replication experiments revealed significantly lower GLuc activity levels during infectivity 
experiments. Constructs JGN3-4 and JGN3-6 showed GLuc activities below 8x103 RLU at all 
measured time points. Levels were 1000 to 10000 fold lower than WT levels. Construct 
JGN3-7 showed reduced GLuc activities during infectivity experiments. Values were between 




5.7x104 and 1.2x105 RLU using supernatant collected 72 and 96 hours post-transfection. 
Values were 10 fold higher compared to JGN3-4 and JGN3-6 and 100 fold lower than WT 
GLuc activities. 
 
Figure 29   Infectivity results of JGN3 constructs with changes within domain 3 alpha helix 20 and 21. Cells were infected 
with collected medium (24h, 48h, 72h and 96h post-transfection) from transfection experiments. Cells were washes after 
24h and incubated in fresh medium for another 48h. Data represents secreted GLuc activity over time in relative light units 
(RLU). Wild-type Jc1 (WT) is shown as a positive control. Further controls mock, GNN and ∆core (described above) are also 
shown. Constructs with severe defects in replication are highlighted red. Constructs with reduced replication are 
highlighted orange. Results represent at least two to three individual rounds of experiments. Error bars indicate standard 
deviation of the mean. 
 
3.3.1.2 Infectivity of constructs with changes within NS3hel domain 3 alpha helix 14, 15 and 
16 
 
Within alpha helix 14, 15 and 16 of NS3hel domain 3 five constructs – JGN3-8, JGN3-9, 
JGN3-10, JGN3-12 and JGN3-15 – showed ability to replicate efficiently. JGN3-9 showed 
GLuc activities of 9x106 and 1.1x107 RLU using 72 and 96 hour supernatant to infect naïve 
cells. Both JGN3-8 and JGN3-10 showed decreased GLuc activity levels compared to WT. 
JGN3-8 revealed GLuc activities of 1.3x105 and 3.5x105 RLU at 72 and 96 hour time points 
used for infections. JGN3-10 showed comparable results. Values were 3.8x105 and 4.4x105 
RLU using 72 and 96 hour supernatants. Values of both constructs were around 100 fold 
lower than WT values. JGN3-15 showed slightly decreased GLuc activities of about 10 fold 
lower than WT levels. Infecting cells with supernatant harvested 72 and 96 hours post-















































































GLuc activity values of construct JGN3-12, that was able to replicate, were below 2x104 RLU 
at all scanned time points. Values were significantly (about 10000 fold) lower than WT GLuc 
activities.  
Remaining three mutants with changes within alpha helix 15 or 16 – JGN3-11, JGN3-13 and 
JGN3-14 – were not able to replicate. All three constructs showed around 10000 fold lower 
GLuc activities compared to WT values. JGN3-11 ranged around 2x103 RLU during all 
scanned time points. JGN3-13 showed amounts lower than 3x103 RLU. GLuc activities of 
JGN3-14 were between 2x103 and 4.7x103 using supernatant harvested 24 to 96 hours post-
transfection. 
 
Figure 30  Infectivity of JGN3 constructs with changes within domain 3 alpha helix 14, 15 and 16. Cells were infected with 
collected medium (24h, 48h, 72h and 96h post-transfection) from transfection experiments. Cells were washes after 24h and 
incubated in fresh medium for another 48h. Data represents secreted GLuc activity over time. Wild-type Jc1 (WT) is shown as 
a positive control. Further controls mock, GNN and ∆core (described above) are also shown. Constructs with severe defects in 
replication are highlighted red. Constructs with reduced replication are highlighted orange. Results represent at least two to 
three individual rounds of experiments. Error bars indicate standard deviation of the mean. 
 
3.3.2 Constructs with changes within NS3hel domain 2 
 
All five screened mutations within NS3 helicase domain 2 (JGN3-16, JGN3-17, JGN3-18, 
JGN3-19, JGN3-20) caused severe or moderate defects in replication. All of these constructs 














































































Within infectivity experiments using supernatants 24, 48, 72 and 96 hours post-transfection, 
GLuc values of JGN3-16 ranged from 1.8x103 to 6x104 RLU. JGN3-17 GLuc activity values 
stagnated around 3x103 at all tested time points. Furthermore, both JGN3-18 and JGN3-19 
revealed GLuc activity levels under 2x103 RLU at all time points scanned for infection. JGN3-
20 showed reduced GLuc activities compared to WT with values between 2.7x103 and 5x104 
RLU infecting naïve cells with supernatant harvested 24 to 96 hours post-transfection. 
Results reveal that none of the constructs with changes in domain 2 were able to infect naïve 
Huh7.5 cells.  
 
Figure 31 Infectivity of JGN3 constructs with changes within domain 2. Cells were infected with collected medium (24h, 
48h, 72h and 96h post-transfection) from transfection experiments. Cells were washes after 24h and incubated in fresh 
medium for another 48h. Data represents secreted GLuc activity over time. Wild-type Jc1 (WT) is shown as a positive 
control. Further controls mock, GNN and ∆core (described above) are also shown. Constructs with severe defects in 
replication are highlighted red. Results represent two to three individual rounds of experiments. Error bars represent 
standard deviation of the mean. 
 
3.3.3 Constructs with changes within NS3hel domain 1 
 
Within NS3hel domain 1 only construct JGN3-24, containing the A217R mutation, showed 
efficient replication. The other changes within domain 1 lead to severe or moderate defects in 
replication.  
Replication defective mutants JGN3-21, JGN3-22, JGN3-23 and JGN3-25 showed 





























































than WT values. JGN3-21, JGN3-22 and JGN3-23 showed GLuc activity below 3x103 RLU. 
JGN3-25 results ranged between 5x103 and 2.6x103 RLU. 
Replication competent mutant JGN3-24 also showed significantly lower GLuc levels than 
WT. Values were between 1.6x103 and 2x104 RLU, showing that JGN3-24 is able to replicate 
but not to infect naïve Huh7.5 cells.  
Results showed that none of the examined constructs with changes in domain 1 were 
infectious, not even JGN3-24 which replicated efficiently. 
 
 
Figure 32   Infectivity of JGN3 constructs with changes within domain 1. Cells were infected with collected medium (24h, 
48h, 72h and 96h post-transfection) from transfection experiments. Cells were washes after 24h and incubated in fresh 
medium for another 48h. Data represents secreted GLuc activity over time. Wild-type Jc1 (WT) is shown as a positive 
control. Further controls mock, GNN and ∆core (described above) are also shown. Constructs with severe defects in 
replication are highlighted red. Constructs with reduced replication are highlighted orange. Results represent at least two to 
three individual rounds of experiments. Error bars represent standard deviation of the mean. 
 
3.3.4 Summary of infectivity experiments 
 
15 studied constructs that were shown to have severe or moderate defects in replication – 
JGN3-1, JGN3-4, JGN3-6, JGN3-11, JGN3-13, JGN3-14, JGN3-16, JGN3-17, JGN3-18, 
JGN3-19, JGN3-20, JGN3-21, JGN3-22, JGN3-23 and JGN3-25 – were shown to be non-
infectious. Construct JGN3-7 that showed reduced replication also showed reduced GLuc 







































































Out of nine mutants that were shown to be replication competent six constructs – JGN3-3, 
JGN3-5, JGN3-8, JGN3-9, JGN3-10 and JGN3-15 – were able to infect naïve Huh7.5 cells 
as efficient or almost as efficient as WT. Most interestingly, three mutants were able to 
replicate but were not infectious. These mutants include two constructs with changes in 
domain 3: JGN3-2 with substitutions T612A, H613A within α-helix 21 and JGN3-12 with 
changes T537A, T540A and H541A within α-helix 15 of domain 3. One construct showing 
these properties could be determined within domain 1: JGN3-24 that includes mutation 
A217R within α-helix 5. Due to these findings these residues are candidates to be involved in 
virion assembly. These three mutants were used for further studies and were the center of 
this thesis. 
3.4 Anti-NS5a staining 
 
Replication and infectivity results were confirmed by immunostaining for NS5a. Huh 7.5 cells 
were transfected, fixed and stained 72h post-transfection. Successfully transfected cells that 
provide efficient HCV replication can be positively stained for NS5a as well as infected cells 
with efficient HCV replication. Cells were fixated, incubated with an anti-NS5a monoclonal 
antibody and stained. Cells that include a certain amount of NS5a can be detected. Results 
of immunostaining confirmed data of HCV replication and infectivity results.  
Constructs that were shown to replicate due to its GLuc activity levels comparable to WT 
could be positively stained for NS5A. Within mutants that revealed defects in replication with 
significantly low GLuc activity levels, NS5A could not be detected with immunostaining. 
Constructs JGN3-4, JGN3-6, JGN3-20 and JGN3-21 that had reduced GLuc activities within 
replication experiments were stained negatively for NS5A. However, JGN3-7 that also 
revealed reduced GLuc activities could be positively stained for NS5A.  
Furthermore, these experiments were able to confirm the mutant’s competence of infectivity. 
Constructs with GLuc levels alike WT within infectivity experiments were confirmed to be as 
infectious as WT. NS5A could be positively stained in these cells. Staining results of 
constructs with severely low GLuc activities were negative. Cells infected with supernatant 
from JGN3-7, JGN3-8 and JGN3-10, that showed around 10 fold lower GLuc activities 
compared to WT, could be positively stained and shown to be infectious within these 























WT  + + 
  
GNN - -   
∆ core + - 
  
JGN3-1 - -   
JGN3-2 + - 
  
JGN3-3 + + 
  
JGN3-4 reduced -   
JGN3-5 + + 
  
JGN3-6 reduced -   
JGN3-7 reduced reduced 
  
JGN3-8 + reduced 
  
JGN3-9 + + 
  
JGN3-10 + reduced 
  
JGN3-11 - -   
JGN3-12 + - 
  
JGN3-13 - -   
JGN3-14 - -   
JGN3-15 + + 
  
JGN3-16 - -   
JGN3-17 - -   
JGN3-18 - -   
JGN3-19 - -   
JGN3-20 reduced -   
JGN3-21 reduced -   
JGN3-22 - -   


















JGN3-23 - -   
JGN3-24 + - 
  
JGN3-25 - -   
Figure 33  Summary of replication and infectivity experiments and NS5a immunostaining results. Efficient replication and 
infectivity in the GLuc experiments are marked by +, defects in replication or infectivity with – and reduced replication by r. 
Results of staining experiments are represented by colored cell models; blue cells represent unstained cells and brown cells 
represent positive staining of NS5a. Results represent at least two to three individual rounds of experiments. 
 
3.5 Studying HCV virus particle assembly: JGN3-2, JGN3-12 and JGN3-24 – 
constructs that were able to replicate but not to be infectious  
 
Three of 25 screened constructs showed the ability to replicate but did not infect naïve Huh 
7.5 cells. These constructs that contain mutations within α-helix 21 and α-helix 15 in domain 
3 and within α-helix 5 of domain 1 are interesting for studying the production of infectious 
HCV particles.  
The shown phenotypes predestinate the mutants to serve as models to study the still 
unknown process of HCV assembly. Some questions have to be answered to determine the 
lack of infectivity of these mutants. It has to be examined if the problem can be found within 
the process of virus particle release or assembly of viral particles. Furthermore, it has to be 
determined if intracellular infectious viral particles can be formed or if these mutations lead to 
a defect in an earlier step of virion assembly. Constructs were also passaged at cell culture 
experiments for an extended period of time studying the effect of long term incubation and 
changes of this highly mutating virus.  
Another question was, whether these mutations influence the formation of a newly described 
complex with NS2 and the viral glycoproteins or if they influence viral assembly and 
infectivity in another way.  
Characteristics of JGN3-2, JGN3-12 and JGN3-24 and results experiments described above 
are pooled in figure 34. 





Figure 34  JGN3-2, JGN3-12 and JGN3-24 – mutations, replication and infectivity. (A) Jc1/GLuc2 construct used in these 
studies. NS3hel domains are colored yellow, lightblue and green. Mutations within JGN3-2 (T612A, H613A), JGN3-12 
(T537A, T540A, H541A) and JGN3-24 (A217R) are shown. (B) Ribbon structure of NS3hel. Domains are colored yellow, 
lightblue and green according to coloring above. Mutation sites are highlighted red. (C) Summary of replication and 
infectivity data of JGN3-2, JGN3-12 and JGN3-24. Curves represent GLuc activity in relative light units (RLU). Black curves 
show replication 24h, 48h, 72h and 96h post-transfection. Blue curves show infectivity of native Huh 7.5 cells infected with 
medium collected in transfection experiments at mentioned time points. (D) NS5a immunostaining of Huh 7.5 cells post-
transfection and post-infection. Staining confirms results of GLuc reporter virus experiments. WT, ∆core, JGN3-2, JGN3-12 
and JGN3-24 replicate in Huh 7.5 cells. NS5a is detected by anti-NS5a staining (as described in ‘Material and Methods’ p.40) 
within the cells. Just WT Jc1/GLuc2 is able to infect native Huh 7.5 cells. NS5a cannot be detected within the remainder of 
infection experiments.  Results represent at least three individual rounds of experiments. 
 




3.5.1 Release of viral particles 
 
As described above mutants that were able to replicate but did not show to be infectious 
(JGN3-2, JGN3-12 and JGN3-24) were studied closer. Different reasons could cause the 
defect in infectivity of these mutants. The inserted mutations could inhibit the release of viral 
particles. Another theoretical explanation could be that viral particles are released but not 
infectious. To determine between these two possibilities the amount of viral RNA within the 
cell culture medium was measured by quantitative RT-PCR as the amount of HCV RNA 
within the cell culture medium represents released viral particles. Huh 7.5 cells were 
transfected and medium was used to measure the amount of RNA present in the medium at 
6 days post-transfection. 
 
 
Figure 35   RNA release of infectivity-defective NS3hel mutants. The amount of RNA was measured by quantitative RT-PCR 
6d post-transfection. Results represent at least three individual rounds of experiments. Error bars show standard deviation 
of the mean. 
 
Measurements showed that WT Jc1/GLuc2 efficiently released viral particles into the cell 
culture medium. An average amount of 5.7x106 copies/ml was release into the medium of 
cells transfected with WT RNA. Mock control did not release viral RNA into the cell culture 
medium. Replication defective control GNN released a mean of 7885 RNA copies/ml into the 
cell culture medium. An average of 18150 RNA copies/ml was measured in supernatant from 
cells transfected with ∆core which lacks the production of viral particles. Within medium of 
cells transfected with JGN3-2 RNA an average of 73700 HCV RNA copies/ml could be 













































copies/ml was measured. An average of 10363 RNA copies/ml could be meted in 
supernatant collected of cells transfected with JGN3-24 RNA. In comparison to WT all 
studied constructs revealed RNA levels 100 fold lower than WT levels.  
3.5.2 Intracellular infectious particles 
 
To determine whether the intracellular formation of viral particles of the mutants is intact, 
intracellular infectivity was compared to extracellular infectivity of the supernatants. HCV 
particles were shown to be assembled intracellular. Particles are thought to undergo 
maturation within the cell and are released afterwards as the buoyant density of intracellular 
particles differs from the one of mature extracellular virions (Gastaminza et al. 2006). To 
resolve if mutations within RNA of JGN3-2, JGN3-12 and JGN3-24 influence the intracellular 
formation of virus particle release cells were harvested 48h post-transfection, freeze-thawed 
a couple of rounds and the cell lysate was used to infect naïve Huh 7.5 cells (‘Material and 
Methods’ p. 39). 
Comparing intracellular and extracellular infectivity of the mutants, no significant difference 
between both could be shown regarding all studied constructs. WT Jc1/GLuc2 GLuc activity 
values were 3.1x107 RLU when measured extracellular, intracellular values showed a mean 
of 1.8x106 RLU. Non infectious controls mock, GNN and ∆core showed average GLuc 
activities around 2x103 RLU screening intracellular as well as extracellular infectivity.  
Domain 3 mutant JGN3-2 did not show significant difference comparing intracellular and 
extracellular infectivity. Mean values were 4.7x104 RLU when measuring intracellular 
infectivity and 1.3x104 RLU measuring extracellular infectivity. Intracellular and extracellular 
infectivity of JGN3-12 did also not reveal significant differences. Mean intracellular GLuc 
activities were 9.1x103 RLU. Compared mean extracellular values were 1x104 RLU. Mutant 
JGN3-24 with changes within NS3hel domain 1 showed similar results. Intracellular infectivity 
levels were 4.1x103 RLU and did not differ significantly from extracellular GLuc activity values 
of 5x103 RLU.  
All scanned mutants could not infect naïve Huh7.5 cells neither when using extracellular cell 
culture medium nor using intracellular cell lysates.  
 





Figure 36  Intracellular infectivity vs. extracellular infectivity of NS3hel mutants. Cells were transfected with RNA of the 
mutants, 48h post-transfection cells were lysed and used to infect native Huh 7.5 cells. Results represent at least three 
individual rounds of experiments. Error bars represent standard deviation of the mean. 
 
3.5.3 Physical interactions of NS3hel with NS2 
 
The Lindenbach laboratory works on the identification of a complex which is essential for 
virus particle assembly and contains NS3, NS2 and the envelope glycoproteins. The 
involvement of NS2 in this complex as a coordinator between E1 and E2 and NS3 was 
published recently (Stapleford and Lindenbach 2011). As this complex is shown to be 
essential for HCV assembly, the involvement of NS3hel in this complex is interesting to 
determine and was studied in this thesis. Whether the changes T612A, H613A, T537A, 
H540A, H541A and A217R within constructs JGN3-2, JGN3-12 and JGN3-24 influence the 
formation and stability of the NS2-NS3 complex was studied.  
To check interactions between NS2 and NS3hel pulldown experiments were performed. 
Constructs expressing the biotin acceptor peptide (BAP) at the amino-terminal end of NS2 
were used. High-affinity interactions between biotin and streptavidin can be used to isolate 
proteins as described in the literature. The previously described mutations within JGN3-2, 
JGN3-12 and JGN3-24 were cloned into BAP-expressing full length HCV constructs named 
Jc1/bioNS2. Furthermore, Huh 7.5 cells expressing the E.coli biotin ligase BirA were 
transfected with RNA of the Jc1/bioNS2 mutants. WT Jc1/bioNS2 and mock, GNN and ∆core 



























































of a biotin molecule to the lysine residue of the BAP at the amino terminal end of NS2. This 
biotin molecule can interact with streptavidin to separate NS2 and proteins that are 
complexed with NS2. Stapleford and Lindenbach (2011) showed that the BAP-containing 
constructs do not influence viral replication or infectivity compared to untagged Jc1. 48 hours 
post-transfection cells were lysed. The lysate was mixed with streptavidin magnetic beads 
and separated on a magnetic rack to capture biotinylated proteins. NS2 and proteins that are 
bound to NS2 were purified from the remainder proteins of the cells. Proteins were separated 
by SDS-PAGE and transferred to PVDF membranes. Indicated proteins were immunoblotted. 
This system was used to determine whether assembly defective NS3hel mutants physically 
interact with NS2 or if the mutations inhibit these interactions. 
All experiments were done with Huh 7.5(BirA) cell lysates harvested 48h post-transfection. 
Total cell lysate was blotted to show proteins present within the lysate prior to protein 
separation. This was compared to the cell lysate after protein separation with the previously 
described system. 
Within total cell lysates both proteins NS2 and NS3 could be detected prior to protein 
separation within cells transfected with WT Jc1/BioNS2 as well as with mutants JGN3-
2/BioNS2, JGN3-12/BioNS2 and JGN3-24/BioNS2. Proteins NS2 and NS3 migrated with 
molecular masses of 24 kDa (NS2) and 70 kDa (NS3). Results confirmed that these proteins 
were present as viral replication is intact.  
WT Jc1 represents a control that did not include the BAP at the amino terminal end of NS2. 
Untagged WT Jc1 showed a distinct band at 23 kDa (NS2) lacking the AP-sequence and at 
70 kDa (NS3). Mock control did not show any band as it did not include any HCV proteins.  
All of the screened mutants and controls produced proteins NS2 and NS3. An equal amount 
of produced proteins compared to the WT Jc1/BioNS2 could be detected. The mutants 
efficiently replicated and produced viral proteins. 
After protein separation of NS2 and NS2-bound proteins, WT Jc1/BioNS2 showed a distinct 
band at 24 kDa (NS2). NS3 was also present in the lysate after separation. A distinct band 
was detected at 70 kDa. Both, NS2 and NS3 could be captured and detected with the 
described system. As just NS2 including the BAP can be bound to the streptavidin beads 
NS3 had to be bound to NS2 to show up after separation.  
Furthermore, constructs JGN3-2/BioNS2, JGN3-12/BioNS2, JGN3-24/BioNS2 included the 
tagged NS2 and could be successfully biotinylated and separated with the streptavidin 
system.  
JGN3-2/BioNS2 with mutations T612A and H613A within NS3hel domain 3 also showed a 
distinct band at 24 kDa detecting NS2. Furthermore, NS3 could be detected migrated in the 




gel with a molecular mass of 70 kDa. The NS3 band of bound JGN3-2/BioNS2 is comparable 
to WT Jc1/BioNS2.  
Bound JGN3-12/BioNS2 including mutations T537A, T540A and H541A showed a distinct 
band at 24 kDa (NS2). Detected NS3 band at 70 kDa showed a significant difference to WT 
Jc1/BioNS2. A weak band could be detected but it appears thinner compared to bound WT 
Jc1/BioNS2.  
JGN3-24/BioNS2 with mutation A217R within NS3hel domain 1 also showed a strong band 
at 24 kDa detecting NS2. However, NS3 detecting band at 70 kDa is also significantly 
slighter than the bound WT band.  
Results were controlled by WT Jc1 and mock. Untagged NS2 within the Jc1 construct was 
not captured after separation as it cannot be biotinylated. Mock controls remained negative in 
both total cell lysate and lysate after separation as cells were electroporated without RNA.  
Mutations within the mutants JGN3-12 and JGN3-24 did influence NS2-NS3 interactions but 
did not completely disrupt these. However, mutant JGN3-2 seems to not influence protein-
protein interactions between NS2 and NS3. 
 
 
Figure 37  Pulldown of NS2(AP)-containing complexes. Cells were transfected with Jc1/BioNS2 complexes and Jc1. 
Biotinylated proteins were separated with streptavidin beads, eluted in SDS-PAGE sample buffer, separated by SDS-PAGE 
and immunoblotted for NS2 and NS3, as described in ‘Material and Methods’ (p. 43ff). Total shows proteins present in the 
cell lysate before separation. Bound shows proteins separated by streptavidin beads. Results were confirmed by three 










3.6 Long term infectivity - passaging experiments over 12d  
 
To determine the characteristics of HCV constructs JGN3-2, JGN3-12 and JGN3-24 mutants 
were passaged over a period of more than 96h. Supernatants of transfected Huh 7.5 cells 
were collected at 24h, 48h, 72h, 96h, 6d, 9d and 12d to infect native Huh 7.5 cells. Phan et 
al. (2009) described that the Jc1/GLuc construct is stable for up to 4 weeks so the method of 
measuring GLuc activity can be further used as it is still reliable.  
 
Figure 38  Infectivity of JGN3-2, JGN3-12 and JGN3-24 over time. Results represent at least three individual rounds of 
experiments. Error bars represent standard deviation of the mean. 
 
Supernatant of JGN3-2 including mutations T612A and H613A infected native Huh 7.5 cells 
6d post-transfection. GLuc values ranged between 1.6x106 and 1x106 RLU at time points 6 to 
12 days post-transfection. 
Mutants JGN3-12 and JGN3-24 regained infectivity after an average of 9d. GLuc levels of 
JGN3-12 were 5.8x105 and 4.8x106 RLU 9 and 12 days post-transfection. Levels of JGN3-24 
were 1.7x106 and 4.3x106 RLU 9 and 12 days post-transfection. Results were confirmed by 










































3.7 Summary of results 
 
25 HCV constructs with changes in NS3 helicase domains were studied in replication and 
infectivity. 16 mutants showed severe or moderate defects in RNA replication. 6 mutants 
were able to efficiently replicate and produce infectious virus similar to WT values. Three 
mutants were able to replicate but had severe defects in assembly.  
Several residues could be mapped to be essential for viral genome replication. All changes 
made within NS3 domain 2 lead to severe defects in viral replication. Residues E346, P348, 
F349, Y350 and P355 within domain 2 were mapped to be essential for replication. Within 
domain 3 residues E530, E533, D543 and H545 were shown to be involved in replication as 
well as Y618. A couple of other residues in domain 3 seem to influence replication as 
constructs showed reduced replication. These residues within domain 3 included L588, 
K589, P590, T591 and Y618. Within NS3 domain 1 several changes also influenced HCV 
RNA replication. Residues Q221, G222, Y223, D308, Q309, E311 and T312 could be 
mapped playing a role in viral replication. 
NS3 domain 1 and 3 were shown to be involved in HCV virus particle assembly. Residues 
T537, T540, H541, T612 and H613 within domain 3 and A217R in domain 1 were identified 
influencing virion assembly. T612 and H613 influenced reaction kinetics. Changes of T537, 
T540, H541 and A217 induced a severe defect in particle assembly. 
Within this thesis NS3 domain 1 and 3 could be shown to be essential for virus particle 
assembly at an early step of the assembly process prior to release and formation of 
intracellular infections particles.  
NS3 physically interacts with NS2. Changes within domain 1 and 2 could be shown to 
influence interactions but not to inhibit them completely.  
Furthermore, the effect of the lack of HCV in RNA proofreading and its high mutation rate 
could be demonstrated. The virus is able to regain infectivity in cell culture after long term 
incubation. 
 







Hepatitis C virus non structural protein 3 is a multifunctional protein with important roles 
within the viral life cycle. It is essential for viral replication as a part of the membrane-
associated replicase complex. NS3 contains protease, NTPase and helicase activities 
necessary for viral replication. Next to its role in replication it is also suggested that NS3 
helicase domain is involved in virus particle assembly.  
The dual role of the NS3 helicase domain in the viral life cycle is demonstrated by the data 
presented here.  
4.1 Role of NS3hel in viral replication 
 
Helicases are involved in replication by binding and unwinding double-stranded DNA or RNA 
making the templates accessible for replication. Single-stranded Hepatitis C viruses also 
require helicase activity for RNA replication. Even though the precise role of Hepatitis C NS3 
helicase is still unclear, it was previously shown to be essential for viral RNA replication 
(Kolykhalov et al. 2000; Lam and Frick 2006). It is hypothesized that single-stranded RNA 
viruses require helicase activity to separate partially double-stranded replication 
intermediates or pairs between templates and their nascent complementary strands (Kadaré 
and Haenni 1997). Within this study several residues within all three major NS3 helicase 
domains could be identified playing a role in viral replication. Mutational changes of these 
residues in the context of the genotype 2a full length replicon system lead to defects in viral 
replication.  
As helicase activity is essential for replication, defects must somehow influence enzymatic 
activities of NS3hel. Induced changes of surface residues tried to avoid previously described 
sites that are essential for helicase activity like the conserved helicase motifs and NTP and 
nucleic acid binding sites. Even though these sites were avoided mutations could have lead 
to changes in protein conformation or intra-molecular interactions. Another explanation for 
the observed replication defects could be extra-molecular interactions. Earlier studies 
revealed interactions between NS3 and the RdRp NS5B, NS5A and NS4B. They are 
supposed to form a membrane-associated replication complex which is a hallmark of 
positive-strand RNA viruses. In addition, it is described that NS3-4A protease enhances NS3 
helicase activity suggesting its involvement in the replication complex (Zhang et al. 2005; Gu, 
B et al. 2005). Gosert et al (2003) described that NS4B is capable of forming a complex with 
NS3 suggesting it might play a role in recruiting NS3 to the site of RNA replication, the so-
called membranous web. Moradpour et al. (2004) showed that NS3, NS4B and NS5B co-




localize within the cell. Zhang et al (2005) described that NS3-4A protease might mediate 
NS3hel-NS5B-interactions during replication. Mutated NS3hel surface residues as studied 
here might influence protein-protein interactions resulting in replication defects.  
 
 
Figure 39 Replication complex. Suggested protein-protein interactions are indicated with arrows. 
 
 
Within NS3hel domain 3 data presented here revealed that α-helices 15, 16, 20 and 21 play 
a role in HCV replication. Residues Y618, L588, K589, E530, E533, D543, H545, D543 and 
H545 were identified being involved in replication.  
Only a couple of residues within domain 3 essential for HCV replication were described in the 
literature so far. Previous studies of Lin and Kim, JL (1999) reported domain 3 residue W501 
within α-helix 13 to be important in the replication process by anchoring the nucleic acid to 
the active centre of the enzyme. Lam and Frick (2006) performed further studies with several 
NS3hel residues including W501. They described that the aromatic side chain of W501 is 
essential for unwinding RNA supporting replication. Another residue within domain 3 
described by Lam and Frick is E493 which is located in the same α-helix as W501 and also 
contacts the nucleic acid. Furthermore, domain 3 residues H528, F531, W532 and F536 
within α-helix 15 were described to be important for proper NS3 protein folding (Lam et al. 
2003).  
Within experiments of this thesis two residues important for HCV replication could be 
identified within alpha-helix 15. E530 and E533 were located in this area. These findings 
underline that α-helix 15 is important for the active conformation of NS3hel. Furthermore, α-
helix 15 is located right beside α-helix 13 with residues W501 and E493 that were shown to 
interact directly with the nucleic acid. Though the role of α-helix 15 might be to stabilize the 
conformation of NS3hel, especially stabilizing α-helix 13 and the nucleic acid binding groove.  




Moreover, residues D543 and H545 within α-helix 16 influence viral replication. These 
residues might also stabilize the conformation of α-helix 13 and the nucleic acid binding 
groove as α-helix 16 is also lining α-helix 13 maybe stabilizing both α-helix 15 and 13. But 
due to its location α-helix 16 might also interact directly with the nucleic acid. To determine 
whether or not these residues interact with RNA or DNA further studies would be necessary.  
 
 
Figure 40 Involvement of studied domain 3 residues in replication. NS3hel domains 1, 2 and 3 are marked yellow, blue and 
green. Residues studied here are marked red and residues implicated in replication elsewhere are highlighted orange. 
Arrows indicate hypothesized interactions with the nucleic acid, with the NTP or intramolecular interactions. Dashed arrows 
indicate extramolecular protein-protein interactions. Models were rendered with PyMOL, Protein Data Bank code 3KQL. (A) 
Residues within alpha helix 15 and 16 implicated in replication. Α-helices 15 and 16 might stabilize active conformation of 
the nucleic acid binding cleft or interact with other NS proteins. (B) Residues within alpha helix 20 and 21 implicated in 
replication. Α-helices 20 and 21 are likely important for protein-protein interactions during replication. 
 
However, studied surface residues Y618 within α-helix 21 and L588 and K589 within α-helix 
20 are located more turned away from α-helix 13. It is a possibility that they also stabilize α-
helix 13, but they could more likely be considered to be essential to form interactions 
between NS3 and other NS proteins. Co-localization of NS3 and NS5B as well as with NS4B 
is described in the literature but no residues involved in these interactions were described so 
far (Ishido et al. 1998; Piccininni et al. 2002).  
Interestingly, within this thesis, changes P590A and T591A in α-helix 20 that did not influence 
replication, restored defects of L588A and K589A when all four residues were combined in 
one mutant (JGN3-5). They seem to compensate conformational changes or charges fixing 
the replication defect. 
As shown in this thesis NS3hel domains 1 and 2 were especially sensitive for changes. 
These findings underline their superior role in HCV replication.  




Conserved helicase motifs I, Ia, Y, Ib, Ic, II, and IIII are located within domain 1. Motifs V, 
IVa, V and VI are located within domain 2. Both domains are important for NTPase activity 
and nucleic acid binding. Earlier studies were able to reveal residues important for NS3 
helicase activities located in domains 1 and 2. Those studies focused on residues at RNA 
binding and NTPase activity sites. Examined residues influence helicase activity by 
decreasing nucleic acid binding or NTPase activity. Lin et al. (1999) revealed several 
residues that appear to stabilize interactions between NS3hel and the nucleic acid. γ-OH 
groups of T269 of domain 1 and T411 of domain 2 could be identified to be essential for 
nucleic acid binding. Unwinding activity and NTPase stimulation was abolished by changing 
these residues (Lin and Kim, JL 1999). W-501 of domain 3 (as described above) and V432 of 
domain 2 were further studied by different groups (Preugschat et al. 2000; Tai et al. 2001). 
These residues are implicated of being essential for unwinding activity. Considering the 
inchworm model these residues are believed to act as an anchor for the nucleic acid during 
conformational changes of the enzyme. Furthermore Tai et al. (2001) identified other 
residues essential for helicase activity. Residues within conserved Walker A and Walker B 
motifs as well as residues not located in these motifs were shown to be crucial for NS3hel 
ATPase activity. Domain 1 residues K210, D290, E291, C292 and H293 within the conserved 
motifs revealed a complete loss of ATPase activity when mutated. Outside these motifs 
residues T322, T324 within domain 1 and  Q460 and R461 within domain 2 could be 
identified to be important for NTP hydrolysis. Furthermore, additional conserved motifs 
essential for DNA/RNA binding and strand separation were described by Lam et al. (2003). 
Therefore an Arg-clamp and a Phe-loop structure were described within domain 2. Residue 
R393 was shown to clamp RNA into the implicated binding cleft in presence and absence of 
ATP. Furthermore, interactions between F438 and F444 with domain 3 residues H528, F528, 
W532 and F536 were described to be important for proper protein folding (Lam et al. 2003).  
Studying NS3hel domain 1 and 2 here affirmed the critical role of these domains in helicase 
activity. Within domain 2 residues E346, P348, F349, Y350 and P355 within beta sheet E1 
as well as adjacent residues S342, S343 and T344 could be identified being essential for 
replication. Beta sheet E1 is located relatively close to T411 and R393 that were identified to 
interact with nucleic acids. Residues within βE1 might influence conformation of the nucleic 
acid binding region. Next to being involved in replication by stabilizing active protein 
conformation studied domain 2 residues could also be involved in protein-protein interactions 
with other NS proteins.  
Within domain 1 residues D308, Q309, E311 and T312 located within α-helix 8 on the 
surface of the back of domain 1 as well as residues Q221, G222 and Y223 were shown to be 
essential for viral replication. Residues are outlying of previously described sites identified 
being involved in NTPase activity or nucleic acid binding. Residues might be important for 




proper protein folding. But it is also likely that they interact with other NS proteins. To 
determine between these possibilities further studies have to be done but were not subject of 
this thesis. Interestingly, mutation Q221L was previously described as a cell culture adaptive 
mutation. It was found to enhance virus production in cell culture. Furthermore it was shown 
to suppress assembly defects in NS2 (Ma et al. 2008; Phan et al. 2009). This site seems to 
influence functional RNA binding of NS3-4A. Phan et al. (2009) hypothesized that Q221 
might influence RNA-stimulated interactions of the ATP-binding pocket.  
 
 
Figure 41 Involvement of studied domain 1 and 2 residues in replication. NS3hel domains 1, 2 and 3 are marked yellow, 
blue and green. Residues studied here are marked red and residues implicated in replication elsewhere are highlighted 
orange. Arrows indicate hypothesized interactions with the nucleic acid, with the NTP or intramolecular interactions. 
Dashed arrows indicate extramolecular protein-protein interactions. Models were rendered with PyMOL, Protein Data Bank 
code 3KQL. (A) Domain 2 residues implicated in replication. While residues S342, S343, T344, E346, P348, F349 and P355 
are likely playing a role interacting with other NS proteins during replication, Y350 might also play a role in stabilizing active 
conformation of the nucleic acid binding cleft. (B) Domain 1 residues implicated in replication. Residues Q221, G222, Y223, 




Infectivity screenings confirmed that without efficient replication infectious particles cannot be 
produced as no viral RNA can be packaged. However, several residues that did not or just 
minimally influence replication and infectivity, could be identified to be silent mutations. Sites 
are not involved in both functions. Residues D503, E508,  R512, S548, Q552, P614 and 
K617 do not influence infectivity capability. Interestingly, mutant JGN3-5 that included 
mutations of residues L588, K589, P590 and T591 was replication competent and infectious 
comparable to WT. But mutant JGN3-6 that included only L588 combined with K589 was not 
able to replicate or to be infectious.  JGN3-7 including P590 combined with T591 was able to 




replicate and to be infectious but activity of both functions was decreased. The combination 
of all four mutations restores defects of L588 and K589 alone.  
The most striking findings within the infectivity experiments were represented by JGN3-2, 
JGN3-12 and JGN3-24. These constructs, including changes of residues A217, T537, T540, 
H541, T612 and H614, were able to replicate but lacked the ability to infect naïve Huh7.5 
cells. As the replication machinery could be shown to be intact, these constructs could be 
perfectly used as models to study HCV particle assembly. Changes have to interfere the 
production of infectious viral particles at a post-replication step within the virion production 
pathway. Therefore, the problem has to be either in the formation of viral particles or the 
release of infectious virions. 
 
Figure 42 NS3hel is essential for an early step of particle assembly prior to the formation of intracellular viral particles. 
The figure summarizes steps essential for the formation of infectious viral particles and defects caused by studied 
mutations.  As replication is intact, a post-replication step has to be blocked within JGN3-2, JGN3-12 and JGN3-24. 
 
4.3 JGN3-2, JGN3-12 and JGN3-24 – constructs that were able to replicate but 
not to be infectious  
 
To determine whether the lack of infectivity of JGN3-2, JGN3-12 and JGN3-24 is attributable 
to defects in the release of infectious viral particles or in the process of particle assembly 
further experiments were performed.  
By using qRT-PCR studies the amount of viral RNA released into the cell culture medium 
was measured assuming that a lack of viral RNA within the medium points out a defect in 
assembly or release. If higher RNA levels can be found one can assume that viral particles 
are released but virions are not infectious which might point out a problem in the entry 
process within the viral life cycle. Results revealed that WT was able to replicate RNA and 
assembled and released infectious virions. The mock control did not release viral RNA into 




the cell culture medium as cells were transfected with no viral RNA. Replication defective 
control GNN and assembly defective control ∆core are not able to release viral particles. The 
low amount of viral RNA measured within the cell culture medium is caused by residual 
leftover from the transfection. Another possible cause was described by Lindenbach et al. 
(2005) and other groups. HCV replicons which are able to replicate, release small amounts 
of viral RNA into the cell culture (Wakita et al. 2005). This might explain, why the level of 
RNA within the medium of replication competent ∆core was slightly higher compared to 
replication defective GNN. JGN3-2, JGN3-12 and JGN3-24 show an as low amount of viral 
RNA comparable to the negative controls. These mutants with mutations T612A, H613A, 
T537A, T540A and H541A and A217R did not release HCV RNA into the cell culture 
medium. JGN-2 showed a slightly higher amount of particles released six days post-
transfection. Defects might have been already restored by other mutations in some of the 
experimental rounds carried out. Alternatively, a higher amount of RNA could have been 
secreted into the media.  
Altogether, one can say that none of the three constructs was able to release viral particles 
showing that the defect can be found within the process of particle assembly or the release 
process itself. To determine between these possibilities further experiments were performed. 
To find out whether intracellular infectious HCV particles are produced within the cells 
transfected with the replication competent constructs, intracellular infectivity experiments 
were carried out. Results revealed that none of the examined mutants was able to infect 
Huh7.5 cells showing that no infectious intracellular particles are produced. These results 
implicate that NS3hel is essential for an early step of virus assembly prior to the formation of 
intracellular infectious particles. 
4.3.1 NS3hel and virus particle assembly 
 
The process of HCV particle assembly could not be unraveled to date. Also the complete role 
of the NS3 helicase is not known. Recent studies revealed a novel role for the NS3 helicase 
domain in virus particle assembly. Single mutation Q221L within NS3hel domain 1 was 
shown to compensate NS2 defects in virion production (Ma et al. 2008; Phan et al. 2011). 
Furthermore, Ma et al. described mutation I286V within NS3hel domain 1 to restore changes 
within domain 2 (I399V). These studies revealed evidence for the involvement of the two 
major subdomains 1 and 2 of NS3hel in the process of HCV particle assembly.  
In related helicases of flaviviruses and pestiviruses, like Kunjin virus (KUN), yellow fever 
virus (YFV) and bovine viral diarrhea virus (BVDV), the involvement of NS3 in assembly of 
infectious particles could be described (Agapov et al. 2004; Kümmerer and Rice 2002; Liu et 
al. 2002).  




Due to these findings alanine-scanning mutagenesis of residues located within all major 
NS3hel subdomains was performed within this thesis. Findings, based on experiments using 
the full-length Jc1 replicon-based cell culture system, report the essential role of NS3hel in 
virus particle assembly indentifying residues within domain 1 and 3 that are involved in this 
process.  
Results presented here demonstrating that NS3 helicase domains 1 and 3 are involved in 
HCV particle assembly agree with previous finding of Ma et al. No novel residues within NS3 
domain 2 involved in assembly could be revealed. However, the involvement of NS3hel 
domain 3 could be presented here for the first time.  
Furthermore, the affinity purification system developed by the Lindenbach laboratory was 
used to study protein-protein interactions between NS2 and NS3. The efficiency of this 
system was described recently (Stapleford and Lindenbach 2011) NS2 and associated 
proteins could be captured in the context of genotype 2a virus producing Huh 7.5 cells.  
Data presented here confirm Stapleford and Lindenbach (2011). NS2-NS3 interactions could 
be demonstrated and residues T537, T540 and H541 within domain 3 and A217 within 
domain 1 could be mapped influencing these interactions. 
4.3.2 How does NS3hel contribute to virus particle assembly?  
 
NS3hel mutations affecting virus assembly could be mapped on surface residues within 
domain 1 and 3. It was also demonstrated that enzyme activities, NTPase and helicase 
activity, were not influenced by these mutations as replication was intact. Thus, these 
findings point to the assumption that NS3hel interacts with other HCV proteins or so far 
unidentified host cell proteins within the process of virus particle assembly. 
Stapleford and Lindenbach (2011) revealed that NS2 physically interacts with E1, E2 and 
NS3. It is also thought that p7 and NS4A are a part of an NS2 complex. NS2 is described to 
coordinate interactions between E1-E2 with NS3-4A. It is assumed that these interactions 
within this complex play a central role in virus particle assembly.  
On the basis of these results the role of NS3 helicase in virion assembly and especially in 
this complex was determined here. Assuming that assembly is based on this complex, 
disruption of the complex has to lead to a defect in the assembly of viral components leading 
to a lack of infectivity.  
Further analysis of NS3 helicase residues which are implicated in viral assembly by 
mutational experiments in this study reveal whether the lack of infectivity is caused by 
influencing protein-protein interactions of the described assembly complex. With the newly 
described protein-complex purification system, interactions between NS2 and NS3 could be 
confirmed. Physical interactions between NS2 and wild-type NS3 were demonstrated.  




Furthermore, mutations T537A, T540A and H541A within domain 3 and mutation A217R 
within domain 1 revealed significant decreases in NS2-NS3 interaction levels. These 
residues that are proven to be essential for virus particle production affect protein-protein 
interactions. Affinity purification experiments revealed decreased levels of NS2-NS3 
interactions, but a certain fraction of NS2-NS3 complexes were proven.  
NS2 is thought to be stabilized by NS3 forming a dimeric proteolytically active NS2-3 
protease conformation (Schregel et al. 2009). Interactions between NS2 and NS3 are further 
supposed to be involved in the formation of the replicase complex (Kiiver et al. 2006). These 
NS2-3 interactions cannot be excluded getting captured within the pulldown experiments 
which would explain these findings. 
Whereas, another possible explanation might be that interactions between NS2 and NS3 are 
unstable but not all complexes are disrupted resulting in a significantly decreased amount of 
intact complexes leading to a lack of infectivity. 
The involvement of NS3hel domain 1 and domain 3 in virus assembly could be determined in 
an early step of the assembly process prior to the formation of intracellular infectious virions 
assuming that the described complex is involved in assembly during this early step.  
Previous studies suggested that cytoplasmic lipid droplets (LD) play a key role in the 
formation of viral particles. Core and LDs were described by Boulant et al. (2007) and Jones, 
DM and McLauchlan (2010) to be involved in initiation of viral assembly. Core was suggested 
to coat lipid droplets and recruit NS proteins and replication complexes to LD and associated 
membranes (Miyanari et al. 2007). Disrupted interactions between core and LD were shown 
to lack down particle assembly (Boulant et al. 2007). It has also been described that core 
affects the localization of LD within the infected cell (Lyn et al. 2010). Furthermore, NS5A 
could be localized on lipid droplets as well. Interactions between NS5A and LDs are further 
described being essential for particle assembly (Tellinghuisen et al. 2008). Miyanari et al. 
(2007) demonstrated that core is directly localized on the surface of lipid droplets while NS5A 
was mainly found within membranous structures surrounding lipid droplets that are core-
associated.  
The membranous structures are assumed to be ER derivates as they were found near the 
ER around the nuclear membrane. These membrane alterations are described for HCV 
replication and assumed as a site for assembly (Bartenschlager et al. 2004). The core-
coated lipid droplets associate with these ER membranes that include HCV proteins. This 
association is thought to be mediated by NS5A.  
As the first step of assembly, core-coated LD and NS5A might build an initiation complex 
arranging assembly-essential components. The NS2-NS3 protein complex might arrange in 
close proximity of the core and NS5A associated LD. It might be important in another early 
step for initiation of viral assembly together with core, NS5A and lipid droplets (LDs). 




Proposed interactions might establish physical closeness between components that build the 
infectious particle, bringing together core and the ER membrane and a complex of E1-E2, 
while NS2 is important for coordination and NS3 handles the viral genome.  
Next to their role of catalyzing the disruption of hydrogen bonds for unwinding duplex DNA or 
RNA, helicases are also described to move along nucleic acid strands in a polar way. King et 
al. (2001) proposed that DNA helicase complexes of adeno-associated virus type 2 can act 
as molecular motors that insert ssDNA into preformed capsids. Based on these findings one 
can assume that helicases are able to target single-stranded genomes to the sites of viral 
packaging, inducing integration of the genome into capsids or forming capsids around it. NS3 
in a complex with NS2 and E1-E2 could function as a RNA binding protein that unwinds 
double stranded RNA and moves ssRNA to the site of endocapsid forming and induces the 
packaging of the viral genome. The protein complex could obtain the role of stabilizing 
interactions and building a physical closeness between components involved in particle 
assembly. Lorenz (2010) described that NS2 forms a dimer for catalytic active conformation. 
It is likely that NS2 is involved in viral assembly in its dimeric form coordinating E1-E2/NS3 
interactions. Due to its relatively small size of 21 kDa dimeric conformation might physically 
simplify maintaining the function as a linker between E1-E2 and NS3 but the actual 
conformation has to be determined in future studies. In flavivirus assembly NS2A was shown 
to induce membrane alterations and play a role in rearranging envelope proteins (Leung et 
al. 2008). HCV NS2 could play a similar role.  
A possible model of the function of the NS2-NS3 complex is proposed here in which NS2 
coordinates the interaction of NS3 with E1-E2 which induces the formation of core as a 
nucleocapsid around the viral genome. Figure 43 shows a model of HCV assembly including 










Figure 43  Model of HCV virus particle assembly. (A) Overview on virion assembly pathway within the infected cell. It is 
thought that early steps of particle assembly are located at ER derived membranes in close proximity to the rough ER and 
cytoplasmic lipid droplets. Further pathway is assumed to include binding of (pre-) VLDL or HDL particles and processing 
within the Golgi apparatus followed by exocytose. (B) Core- and NS5A-coated lipid droplets might initiate assembly inducing 




the formation of a NS2-coordinated complex. Within HCV infected cells core induced lipid droplet dynamics are described  
(Lyn RK et al. 2010). Furthermore, interactions might induce the formation of a complex between E1-E2 with NS2 and NS3. 
NS2 is shown in its dimeric form as recently described in the context of viral its catalytic activity within the NS2-3 protease. 
Monomers are colored blue and lightblue, transmembrane domains are shown in white. NS3 protease domain is colored 
purple, the helicase domain is colored yellow. NS4A is colored green. Viral RNA is simplified. Core, NS5A, E1-E2 and NS4A 
are shown schematically. NS2 and NS3 are shown as protein surface models. Protein models were made on the basis of 3D 
models rendered with PyMOL. Protein data bank entries 2HD0, 3KQL and 3P8N were used. Arrows indicate interactions 
between proteins as revealed here and by Stapleford et al. (2011). (C) Model of proposed complex of E1-E2/NS2/NS3. 
Results of this study indicate that NS2 interacts with NS3hel. Sites implicated in this interaction, T537, T540, H541 and 
A217, are highlighted red. (D) Formation of a virus particle. The NS2 complex coordinates interactions between E1-E2 and 
NS3. NS3hel might coordinate viral RNA to the site of assembly. Interactions between core and E1-E2 lead to encapsidation 
of viral RNA. (E) Virus particle. ER derived membranes including structural proteins are formed around the encapsidated 
viral genome. (F) Mutagenesis of residues T537, T540, H541 and A217 disrupt interactions with NS2 and thereby the 
stability of the complex. Mutations block virus particle assembly as interactions with E1-E2 are reduced and viral RNA is not 
introduced to assembly sites and is not encapsidated.   
 
 
However, mutations T612A and H613A within NS3hel domain 3 do not significantly influence 
NS2-NS3 interactions but lead also to a defect in particle assembly. NS3 was captured in an 
equal level compared to WT genotype 2a construct. Mutations within JGN3-2 have to 
interfere somewhere else in the process of particle assembly. Surface residues T612 and 
H613 seem to influence assembly in a different way than residues T537, T540, H541 and 
A217. They might interact with other HCV proteins or host cell proteins or obtain other roles 




Figure 44  Suggested interactions of NS3hel during HCV particle assembly. The figure shows NS3 in complex with NS2. 
NS3hel residues T612 and H613 within domain 3 are highlighted red. Possible interactions are shown dashed crossed out 
arrows indicate suggested defects that might lead to a lack of particle assembly. Further descriptions are found in the text. 
 




Interactions between NS3 and so far unknown host cell proteins could facilitate genome 
packaging and virion assembly which could be influenced by surface residues of NS3 
domain 1. The protein-protein affinity pulldown system could be further used to determine 
NS3hel interactions with host cell proteins. 
Packaging pathway of the adenovirus type 2 and the rotavirus showed that its genome 
encapsidation is mediated by NTPase or helicase activity (King et al. 2001; Taraporewala 
and Patton 2004). However, as replication and thereby NTPase and helicase activities were 
intact, this role of NS3hel can be ruled out.  
Moreover, NS3hel might be important for coupling RNA replication and packaging. Coupling 
between these functions is previously described for polioviruses (Nugent et al. 1999). As 
NS3 is involved in both viral replication and packaging it could function as a link between 
replication and assembly. Different authors suggested that within the poliovirus context only 
actively replicating RNA could be encapsidated (Baltimore 1969; Nugent et al. 1999). 
Khromykh et al. (2001) demonstrated a functional coupling between the replication and 
packaging of flavivirus RNA. These findings indicate that both complexes, the replication and 
packaging complex, have to be coupled somehow. A protein like NS3 that is involved in both,  
replication and assembly, is predestinated for the role of linking these functions and 
regulating particle assembly. 
Suggesting that helicases are able to control the amount of ssRNA and regulate replication 
by their unwinding activities another possible role of NS3hel in viral assembly could be the 
regulation of virus assembly. By controlling the amount of single-stranded HCV genome 
NS3hel could be a limiting factor for particle assembly.  If no single-stranded genome is 
available for packaging, assembly is blocked. However, controlling only assembly without 
replication seems to be unlikely. There might be other factors that stimulate NS3hel to act in 
assembly instead of replication and that are influenced by the inserted mutations. 
In other RNA viruses, like alpha viruses, an encapsidation signal on the RNA level is required 
for specific genome packaging into infectious particles. A specific sequence is important for 
capsid recognition and initiates the formation of viral nucleocapsids. In flavivirus assembly 
such an encapsidation signal is not yet identified. As identified residues involved in virus 
assembly are well conserved they could possibly represent such a signal sequence. 
However, as residues are located on the surface of the completely folded protein it is more 
likely that they are involved in interactions on the protein level.  
Dentzer et al. (2009) revealed several C-terminal NS2 residues that are required for the 
production of infectious virus particles. These residues did not influence replication or NS2 
protease activity. Determined residues might be involved in protein-protein interactions with 
E1-E2 or NS3. Stapleford and Lindenbach (2011) revealed that NS2 might act as a 
coordinator between NS3 and E1-E2. Interactions between NS3 and E1-E2 were disrupted 




without active NS2. Based on these findings it seems unlikely that NS3 interacts directly with 
E1-E2. NS2 seems to bring together NS3 and E1-E2 to the sites of assembly. But afterwards 
NS3 and E1-E2 might interact directly and these direct interactions may be disrupted by 
introducing the changes to NS3hel. NS2-NS3 interactions would be intact but assembly 
would be blocked at the following step. These speculations have to be studied further.  
Furthermore, the site of HCV replication was identified as ER derived membranous web. 
NS4B induces membrane alterations that provide a location for the replication complex. ER 
derived membrane alterations are also described in the context of virion assembly 
(Bartenschlager et al. 2004). Membrane alterations are thought to be induced by NS2 to 
provide sites for virion assembly alike to NS2A in other flaviviruses (Leung et al. 2008). If 
these membranous structures are recruited from the ER or from other origins is not 
described. As there is a possibility that replication and assembly are linked, the membranous 
web might be the origin of membrane structures for viral assembly sites. NS3 that functions 
in the RNA replication complex could possibly play a role in recruiting these membranes. 
NS3 could also play a role in recruiting ER derivates. But these speculations remain 
unknown so far. 
4.4 Long term infectivity 
 
Next to the assembly studies, the ability of HCV to restore defects in infectivity was 
confirmed. Therefore, transfected Huh7.5 cells were constantly passaged over a period of 
twelve days. All three mutants – JGN3-2, JGN3-12 and JGN3-24 – regained infectivity. 
JGN3-2 regained infectivity of an average of 6 days, JGN3-12 and JGN3-24 after nine days. 
HCV lacks RdRp proofreading activity, which leads to a high mutation rate. Mutations within 
the used mutants fixed the defect in virus assembly. New mutations could have been second 
site changes or reversions to WT.  
As JGN3-2 is regaining infectivity after an average of six days, in contrast to above 
suggestions regarding virion assembly, residues T612 and H613 might only influence 
reaction kinetics within the assembly pathway resulting in a delay of virus particle production. 
A low amount of virions might be produced but not enough for infecting naïve cells. However, 
as replication is intact kinetics of the NS3 helicase enzyme activities cannot be affected 












Understanding the role of NS3hel in virus particle assembly helps to unravel the process of 
the formation of infectious virions. Understanding the role of HCV assembly has potential to 
help finding a way to block infectivity of the virus. Understanding this pathway can lead to 
discover novel ways to interfere HCV infectivity. Finding novel substances to treat hepatitis C 
or to find a vaccine against it depends on understanding every step of the HCV life cycle. 
Virus particle assembly and NS3 might be important targets for future drug developments as 
a mostly undiscovered part of the virus life cycle. 
NS3hel could be shown to be essential for viral particle assembly. It is also shown to interact 
with NS2. To identify the process of HCV particle assembly and the role of NS3hel in this 
process further studies have to carry on the previous work. Interactions between NS3 and 
host cell proteins should be studied. Whether NS3hel functions as a coordinator of ssRNA for 
encapsidation or is just maintaining its unwinding activity has to be confirmed by future 
experiments. One major problem determining these interactions is that RNA binding cannot 
be blocked as replication has to be intact. Furthermore, whether NS3hel acts a linker 
between replication and assembly has to be studied deeper.  
However, results presented here contribute in unraveling HCV particle assembly. Domains 1 
and 3 could be demonstrated being essential for this process and protein-protein interactions 
could be proven being crucial for virion assembly. Domain 3 could be presented to be 















Hepatitis C virus non-structural protein 3 (NS3) is a multifunctional protein that obtains serine 
protease, RNA helicase and NTPase activities. The enzyme is essential for viral RNA 
replication. Its protease domain cleaves the viral polyprotein at multiple sites. Furthermore, 
NS3 has recently been implicated to play a role in virus particle assembly. But its function in 
the assembly process is unknown so far.  
To determine the role of NS3 in HCV particle assembly alanine scanning mutagenesis within 
the NS3 helicase domain of chimerical genotype 2a full length replicons was performed. 25 
mutants with changes of surface residues within the helicase domain were tested. 16 
mutants showed moderate or severe defects in replication. 6 mutants were able to replicate 
and produce infectious virus as efficiently as wild type Jc1. 3 mutants efficiently replicated 
but had severe defects in virus particle assembly. Residues T612, H613 T537, T540, H541 
and A217 within helicase subdomain 1 and 3 were identified being essential for HCV virion 
assembly. Domain 3 could be shown to be involved in particle assembly for the first time. 
Furthermore, RT-PCR and freeze-thawing experiments were used to determine the step 
within the particle assembly process affected by the NS3 helicase domain. The involvement 
of NS3 helicase domains 1 and 3 in virion assembly could be identified at an early step of the 
process prior to the formation of intracellular infectious particles. To determine interactions 
with NS2, protein complexes containing biotinylated NS2 were affinity captured with 
streptavidin magnetic beads. Previously described physically interactions between NS2 and 
NS3 were confirmed and 2 of the assembly defective NS3 helicase mutants were shown to 
influence these interactions but not completely disrupt NS2-NS3 protein complexes. The 
remaining mutant did not influence these interactions. 
Data within this thesis reveal that NS3 helicase is involved in an early step of HCV particle 
assembly. Helicase domain 1 and 3 could be identified to be essential in this process. 
Furthermore, interactions with NS2 seem to play a central role in the assembly process.  
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